You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameFluorouracil
Accession NumberDB00544  (APRD00516, EXPT03204)
TypeSmall Molecule
GroupsApproved
DescriptionA pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]
Structure
Thumb
Synonyms
5-Fluoracil
5-Fluoropyrimidine-2,4-dione
5-Fluorouracil
5-Fluracil
5-FU
Fluoro Uracil
Fluorouracil
Fluorouracilo
Fluorouracilum
Fluouracil
FU
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AdrucilSolution50 mgIntravenousPfizer1995-12-312004-04-08Canada
Adrucil Inj 50mg/mlLiquid500 mgIntravenousAdria Laboratories Of Canada Ltd.1978-12-311996-09-10Canada
CaracCream5 mg/gTopicalDermik Laboratories2000-10-272015-11-30Us
CaracCream5 mg/gTopicalValeant Pharmaceuticals North America2013-06-28Not applicableUs
EfudexCream2 g/40gTopicalValeant Pharmaceuticals North America1970-07-29Not applicableUs
Efudex Crm 5%Cream5 %TopicalValeant Canada Lp Valeant Canada S.E.C.1975-12-31Not applicableCanada
FluoroplexCream10 mg/gTopicalAqua Pharmaceuticals1993-12-03Not applicableUs
Fluoroplex Cream 1%Cream1 %TopicalAllergan Herbert Skin Care Division Of Allergan Inc.1992-12-312011-08-04Canada
FluorouracilSolution50 mg/mLTopicalSolco healthcare U.S., LLC2010-06-01Not applicableUs
FluorouracilSolution20 mg/mLTopicalSolco healthcare U.S., LLC2010-06-01Not applicableUs
FluorouracilCream5 mg/gTopicalMylan Pharmaceuticals2013-07-23Not applicableUs
FluorouracilCream5 mg/gTopicalSpear Dermatology Products2014-10-28Not applicableUs
Fluorouracil Inj 50mg/mlLiquid50 mgIntravenousDavid Bull Laboratories (Pty) Ltd.1993-12-311996-09-10Canada
Fluorouracil InjectionSolution5 gIntravenousAccord Healthcare Limited2014-10-01Not applicableCanada
Fluorouracil InjectionSolution50 mgIntravenousSandoz Canada Incorporated1989-12-31Not applicableCanada
Fluorouracil Injection USPSolution50 mgIntravenousHospira, Inc.1998-11-25Not applicableCanada
TolakCream.04 g/gTopicalHill Dermaceuticals, Inc.2015-08-28Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AdrucilInjection, solution2.5 g/50mLIntravenousTeva Parenteral Medicines, Inc.2003-10-01Not applicableUs
AdrucilInjection, solution50 mg/mLIntravenousTeva Parenteral Medicines, Inc.2003-10-01Not applicableUs
AdrucilInjection, solution5 g/100mLIntravenousTeva Parenteral Medicines, Inc.2003-10-01Not applicableUs
FluorouracilSolution50 mg/mLTopicalTaro Pharmaceuticals U.S.A., Inc.2003-11-05Not applicableUs
FluorouracilInjection, solution50 mg/mLIntravenousPfizer Laboratories Div Pfizer Inc.2012-07-18Not applicableUs
FluorouracilInjection, solution50 mg/mLIntravenousFresenius Kabi2000-07-12Not applicableUs
FluorouracilInjection, solution50 mg/mLIntravenousAccord Healthcare Limited2014-02-01Not applicableUs
FluorouracilCream50 mg/gTopicalTaro Pharmaceuticals U.S.A., Inc.2010-03-05Not applicableUs
FluorouracilInjection, solution50 mg/mLIntravenousPfizer Laboratories Div Pfizer Inc.2012-07-18Not applicableUs
FluorouracilCream5 mg/gTopicalSpear Dermatology Products2015-04-23Not applicableUs
FluorouracilCream50 mg/gTopicalRebel Distributors2008-04-11Not applicableUs
FluorouracilInjection, solution50 mg/mLIntravenousBlue Point Laboratories2014-12-15Not applicableUs
FluorouracilCream50 mg/gTopicalTaro Pharmaceutical Industries, Ltd.2010-03-05Not applicableUs
FluorouracilInjection, solution50 mg/mLIntravenousSagent Pharmaceuticals2016-09-15Not applicableUs
FluorouracilInjection, solution50 mg/mLIntravenousPfizer Laboratories Div Pfizer Inc.2012-07-18Not applicableUs
FluorouracilInjection, solution50 mg/mLIntravenousSandoz2008-09-10Not applicableUs
FluorouracilSolution20 mg/mLTopicalTaro Pharmaceuticals U.S.A., Inc.2003-11-05Not applicableUs
FluorouracilCream50 mg/gTopicalPhysicians Total Care, Inc.2011-09-06Not applicableUs
FluorouracilCream50 mg/gTopicalSpear Dermatology Products2008-04-11Not applicableUs
FluorouracilInjection, solution50 mg/mLIntravenousPfizer Laboratories Div Pfizer Inc.2012-07-18Not applicableUs
FluorouracilInjection, solution50 mg/mLIntravenousSandoz2011-05-02Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
CarzonalTobishi
EfudixMeda
EfurixValeant
FtoruracilVerofarm
Brand mixtures
NameLabellerIngredients
ActikerallCipher Pharmaceuticals Inc.
SaltsNot Available
Categories
UNIIU3P01618RT
CAS number51-21-8
WeightAverage: 130.0772
Monoisotopic: 130.017855555
Chemical FormulaC4H3FN2O2
InChI KeyGHASVSINZRGABV-UHFFFAOYSA-N
InChI
InChI=1S/C4H3FN2O2/c5-2-1-6-4(9)7-3(2)8/h1H,(H2,6,7,8,9)
IUPAC Name
5-fluoro-1,2,3,4-tetrahydropyrimidine-2,4-dione
SMILES
FC1=CNC(=O)NC1=O
Pharmacology
IndicationFor the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.
Structured Indications Not Available
Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedPreventionGastric Cancers / Gastro-esophageal Junction Cancer / Stomach Cancer1
0Not Yet RecruitingTreatmentAdenocarcinoma of the Rectum / Cancer of Rectum / Cancer of the Rectum / Rectal Cancers / Rectum Cancer / Rectum Neoplasms1
0Not Yet RecruitingTreatmentEctropion / Skin Neoplasms1
0RecruitingTreatmentActinic Keratosis (AK)1
1Active Not RecruitingTreatmentAcinar Cell Adenocarcinoma of the Pancreas / Duct Cell Adenocarcinoma of the Pancreas / Recurrent Pancreatic Cancer / Stage IV Pancreatic Cancer1
1Active Not RecruitingTreatmentAdenocarcinoma of the Esophagus / Adenocarcinoma of the Stomach / Adenocarcinomas of the Gastroesophageal Junction / Squamous Cell Carcinoma of the Esophagus / Stage II Esophageal Cancer / Stage II Gastric Cancer / Stage III Esophageal Cancer / Stage III Gastric Cancer1
1Active Not RecruitingTreatmentAdenocarcinoma of the Pancreas / Stage III Pancreatic Cancer1
1Active Not RecruitingTreatmentAdvanced Cancers1
1Active Not RecruitingTreatmentAnal Cancer / Carcinoma of the Appendix / Colorectal Cancers / Esophageal Cancers / Extrahepatic Bile Duct Cancer / Gallbladder Cancer / Gastric Cancers / Gastrointestinal Carcinoid Tumor / Gastrointestinal Stromal Tumors / Liver Cancer / Pancreatic Cancers / Small Intestine Cancer1
1Active Not RecruitingTreatmentCancer of Colon / Cancer of Pancreas / Colon Carcinoma / Colorectal Cancers / Malignant Neoplasm of Large Intestine / Malignant Tumor of Colon / Neoplasms, Pancreatic / Pancreatic Cancers1
1Active Not RecruitingTreatmentCancers1
1Active Not RecruitingTreatmentColorectal Cancers2
1Active Not RecruitingTreatmentColorectal Cancers / Kidney Cancer1
1Active Not RecruitingTreatmentColorectal Cancers / Metastatic Cancers1
1Active Not RecruitingTreatmentEsophageal Cancers / Gastric Cancers1
1Active Not RecruitingTreatmentHead and Neck Cancers2
1Active Not RecruitingTreatmentNeoplasms, Pancreatic1
1Active Not RecruitingTreatmentPancreas Cancer1
1Active Not RecruitingTreatmentPancreatic Cancers1
1Active Not RecruitingTreatmentRectal Cancers1
1Active Not RecruitingTreatmentRecurrent Colon Cancer / Recurrent Rectal Cancer / Stage IVA Colon Cancer / Stage IVA Rectal Cancer / Stage IVB Colon Cancer / Stage IVB Rectal Cancer1
1Active Not RecruitingTreatmentRecurrent Colon Carcinoma / Recurrent Rectal Carcinoma / Stage IVA Colon Cancer / Stage IVA Rectal Cancer / Stage IVB Colon Cancer / Stage IVB Rectal Cancer1
1Active Not RecruitingTreatmentSquamous Cell Carcinoma of the Head and Neck (SCCHN)1
1Active Not RecruitingTreatmentTumors, Solid1
1CompletedDiagnosticRecurrent or Metastatic Colorectal Cancer1
1CompletedPreventionNeoplasms1
1CompletedTreatmentAdenocarcinoma of the Rectum / Mucinous Adenocarcinoma of the Rectum / Signet Ring Adenocarcinoma of the Rectum / Stage IIA Rectal Cancer / Stage IIB Rectal Cancer / Stage IIC Rectal Cancer / Stage IIIA Rectal Cancer / Stage IIIB Rectal Cancer / Stage IIIC Rectal Cancer1
1CompletedTreatmentAdenocarcinoma of the Rectum / Stage II Rectal Cancer / Stage III Rectal Cancer1
1CompletedTreatmentAdenocarcinomas / Colorectal / Metastatic1
1CompletedTreatmentAdvanced Cancers1
1CompletedTreatmentAdvanced Colorectal Carcinoma1
1CompletedTreatmentAdvanced Solid Tumors1
1CompletedTreatmentAdvanced Solid Tumors / Liver Cancer1
1CompletedTreatmentAdvanced Solid Tumors / Metastatic Colorectal Cancers1
1CompletedTreatmentCancer, Breast1
1CompletedTreatmentCancer, Breast / Colorectal Cancers / Head and Neck Cancers / Lung Cancers / Prostate Cancers1
1CompletedTreatmentCancers1
1CompletedTreatmentCarcinoma, Colorectal1
1CompletedTreatmentCarcinomas / Peritoneal Neoplasms1
1CompletedTreatmentCentral Nervous System Malignancies / Ependymomas1
1CompletedTreatmentChildhood Central Nervous System Choriocarcinoma / Childhood Central Nervous System Embryonal Tumor / Childhood Central Nervous System Germ Cell Tumor / Childhood Central Nervous System Germinoma / Childhood Central Nervous System Mixed Germ Cell Tumor / Childhood Central Nervous System Teratoma / Childhood Central Nervous System Yolk Sac Tumor / Recurrent Childhood Brain Stem Glioma / Recurrent Childhood Central Nervous System Embryonal Tumor / Unspecified Childhood Solid Tumor, Protocol Specific1
1CompletedTreatmentChronic Myeloproliferative Disorders / Leukemias / Lymphoma NOS / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Precancerous Conditions / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentColorectal Cancers7
1CompletedTreatmentColorectal Cancers / Diarrhea / Neutropenias1
1CompletedTreatmentColorectal Cancers / Esophageal Cancers / Extrahepatic Bile Duct Cancer / Gallbladder Cancer / Liver Cancer / Lung Cancers / Lymphoma NOS / Pancreatic Cancers / Small Intestine Cancer / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentColorectal Cancers / Lung Cancers1
1CompletedTreatmentColorectal Cancers / Metastatic Cancers1
1CompletedTreatmentColorectal Liver Metastases1
1CompletedTreatmentEsophageal Cancers1
1CompletedTreatmentEsophageal Cancers / Gastric Cancers / Liver Cancer1
1CompletedTreatmentGastro-Intestinal Cancer1
1CompletedTreatmentLymphoma NOS / Neoplasms1
1CompletedTreatmentLymphoma NOS / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentMetastatic Colorectal Cancers1
1CompletedTreatmentMetastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma / Recurrent Adenoid Cystic Carcinoma of the Oral Cavity / Recurrent Basal Cell Carcinoma of the Lip / Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity / Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity / Recurrent Lymphoepithelioma of the Nasopharynx / Recurrent Lymphoepithelioma of the Oropharynx / Recurrent Metastatic Squamous Neck Cancer With Occult Primary / Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity / Recurrent Mucoepidermoid Carcinoma of the Oral Cavity / Recurrent Salivary Gland Cancer / Recurrent Squamous Cell Carcinoma of the Hypopharynx / Recurrent Squamous Cell Carcinoma of the Larynx / Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity / Recurrent Squamous Cell Carcinoma of the Nasopharynx / Recurrent Squamous Cell Carcinoma of the Oropharynx / Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Recurrent Verrucous Carcinoma of the Larynx / Recurrent Verrucous Carcinoma of the Oral Cavity / Stage III Adenoid Cystic Carcinoma of the Oral Cavity / Stage III Basal Cell Carcinoma of the Lip / Stage III Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity / Stage III Inverted Papilloma of the Paranasal Sinus and Nasal Cavity / Stage III Lymphoepithelioma of the Nasopharynx / Stage III Lymphoepithelioma of the Oropharynx / Stage III Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity / Stage III Mucoepidermoid Carcinoma of the Oral Cavity / Stage III Salivary Gland Cancer / Stage III Squamous Cell Carcinoma of the Hypopharynx / Stage III Squamous Cell Carcinoma of the Larynx / Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage III Squamous Cell Carcinoma of the Nasopharynx / Stage III Squamous Cell Carcinoma of the Oropharynx / Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Stage III Verrucous Carcinoma of the Larynx / Stage III Verrucous Carcinoma of the Oral Cavity / Stage IV Adenoid Cystic Carcinoma of the Oral Cavity / Stage IV Basal Cell Carcinoma of the Lip / Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity / Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity / Stage IV Lymphoepithelioma of the Nasopharynx / Stage IV Lymphoepithelioma of the Oropharynx / Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity / Stage IV Mucoepidermoid Carcinoma of the Oral Cavity / Stage IV Salivary Gland Cancer / Stage IV Squamous Cell Carcinoma of the Hypopharynx / Stage IV Squamous Cell Carcinoma of the Larynx / Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IV Squamous Cell Carcinoma of the Nasopharynx / Stage IV Squamous Cell Carcinoma of the Oropharynx / Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Stage IV Verrucous Carcinoma of the Larynx / Stage IV Verrucous Carcinoma of the Oral Cavity / Untreated Metastatic Squamous Neck Cancer With Occult Primary1
1CompletedTreatmentMucinous Adenocarcinoma of the Colon / Mucinous Adenocarcinoma of the Rectum / Recurrent Colon Cancer / Recurrent Rectal Cancer / Signet Ring Adenocarcinoma of the Colon / Signet Ring Adenocarcinoma of the Rectum / Stage IIIA Colon Cancer / Stage IIIA Rectal Cancer / Stage IIIB Colon Cancer / Stage IIIB Rectal Cancer / Stage IIIC Colon Cancer / Stage IIIC Rectal Cancer / Stage IVA Colon Cancer / Stage IVA Rectal Cancer / Stage IVB Colon Cancer / Stage IVB Rectal Cancer1
1CompletedTreatmentNeoplams, Advanced1
1CompletedTreatmentNeoplasms Malignant1
1CompletedTreatmentNeoplasms, Head and Neck1
1CompletedTreatmentPeritoneal Cavity Cancer1
1CompletedTreatmentRecurrent Colon Cancer / Recurrent Rectal Cancer / Stage III Colon Cancer / Stage III Rectal Cancer / Stage IV Colon Cancer / Stage IV Rectal Cancer / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentRecurrent Colon Cancer / Recurrent Rectal Cancer / Stage IV Colon Cancer / Stage IV Rectal Cancer1
1CompletedTreatmentStomach Neoplasms1
1CompletedTreatmentTumors1
1CompletedTreatmentUnspecified Adult Solid Tumor, Protocol Specific14
1Enrolling by InvitationTreatmentMucinous Adenocarcinoma of the Rectum / Rectal Adenocarcinoma / Recurrent Rectal Cancer / Signet Ring Adenocarcinoma of the Rectum / Stage IIA Rectal Cancer / Stage IIA to IIIC Rectal Cancer / Stage IIB Rectal Cancer / Stage IIC Rectal Cancer / Stage IIIA Rectal Cancer / Stage IIIB Rectal Cancer / Stage IIIC Rectal Cancer1
1Not Yet RecruitingTreatmentTumors, Solid1
1RecruitingTreatmentAcinar Cell Adenocarcinoma of the Pancreas / Adenocarcinoma of the Gallbladder / Adenocarcinoma of Unknown Primary / Adult Primary Cholangiocellular Carcinoma / Advanced Adult Primary Liver Cancer / Cholangiocarcinoma of the Extrahepatic Bile Duct / Cholangiocarcinoma of the Gallbladder / Diffuse Adenocarcinoma of the Stomach / Duct Cell Adenocarcinoma of the Pancreas / Intestinal Adenocarcinoma of the Stomach / Localized Unresectable Adult Primary Liver Cancer / Metastatic Carcinoma of Unknown Primary / Metastatic Extrahepatic Bile Duct Cancer / Mixed Adenocarcinoma of the Stomach / Mucinous Adenocarcinoma of the Colon / Mucinous Adenocarcinoma of the Rectum / Newly Diagnosed Carcinoma of Unknown Primary / Signet Ring Adenocarcinoma of the Colon / Signet Ring Adenocarcinoma of the Rectum / Stage III Pancreatic Cancer / Stage IIIA Colon Cancer / Stage IIIA Gallbladder Cancer / Stage IIIA Gastric Cancer / Stage IIIA Rectal Cancer / Stage IIIB Colon Cancer / Stage IIIB Gallbladder Cancer / Stage IIIB Gastric Cancer / Stage IIIB Rectal Cancer / Stage IIIC Colon Cancer / Stage IIIC Gastric Cancer / Stage IIIC Rectal Cancer / Stage IV Gastric Cancer / Stage IV Pancreatic Cancer / Stage IVA Colon Cancer / Stage IVA Gallbladder Cancer / Stage IVA Rectal Cancer / Stage IVB Colon Cancer / Stage IVB Gallbladder Cancer / Stage IVB Rectal Cancer / Unresectable Extrahepatic Bile Duct Cancer1
1RecruitingTreatmentAdenocarcinomas / Neoplasms, Pancreatic / Pancreatic Cancers1
1RecruitingTreatmentAdvanced Gastrointestinal Cancers1
1RecruitingTreatmentAdvanced Solid Tumor Malignancies1
1RecruitingTreatmentCancer of the Esophagus, Gastroesophageal Junction or Stomach1
1RecruitingTreatmentCancer, Breast / Colorectal Cancers / Esophagogastric Cancer / Non-Small-Cell Lung Carcinoma (NSCLC) / Pancreatic Cancers / Tumors1
1RecruitingTreatmentCancers1
1RecruitingTreatmentColorectal Cancers / Liver Metastases1
1RecruitingTreatmentInflammatory carcinoma of the breast1
1RecruitingTreatmentKRAS Mutant Metastatic Colorectal Cancer1
1RecruitingTreatmentMalignant Digestive System Neoplasm1
1RecruitingTreatmentMetastatic Colorectal Cancers1
1RecruitingTreatmentMetastatic Colorectal Cancers / Recurrent Colorectal Cancer1
1RecruitingTreatmentMetastatic Pancreatic Adenocarcinoma1
1RecruitingTreatmentMucinous Adenocarcinoma of the Colon / Mucinous Adenocarcinoma of the Rectum / Recurrent Colon Cancer / Recurrent Rectal Cancer / Signet Ring Adenocarcinoma of the Colon / Signet Ring Adenocarcinoma of the Rectum / Stage IIIA Colon Cancer / Stage IIIA Rectal Cancer / Stage IIIB Colon Cancer / Stage IIIB Rectal Cancer / Stage IIIC Colon Cancer / Stage IIIC Rectal Cancer / Stage IVA Colon Cancer / Stage IVA Rectal Cancer / Stage IVB Colon Cancer / Stage IVB Rectal Cancer1
1RecruitingTreatmentNeoplasms Metastasis / Neoplasms, Colorectal1
1RecruitingTreatmentNeoplasms, Colorectal1
1RecruitingTreatmentPancreatic Adenocarcinoma1
1RecruitingTreatmentPancreatic Cancers1
1RecruitingTreatmentRecurrent Rectal Cancer / Stage IIA Rectal Cancer / Stage IIB Rectal Cancer / Stage IIC Rectal Cancer / Stage IIIA Rectal Cancer / Stage IIIB Rectal Cancer / Stage IIIC Rectal Cancer1
1RecruitingTreatmentRecurrent Salivary Gland Cancer / Recurrent Squamous Cell Carcinoma of the Hypopharynx / Recurrent Squamous Cell Carcinoma of the Larynx / Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity / Recurrent Squamous Cell Carcinoma of the Nasopharynx / Recurrent Squamous Cell Carcinoma of the Oropharynx / Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Recurrent Verrucous Carcinoma of the Larynx / Recurrent Verrucous Carcinoma of the Oral Cavity / Salivary Gland Squamous Cell Carcinoma / Tongue Cancer1
1RecruitingTreatmentTumors, Solid1
1RecruitingTreatmentUnresectable Advanced Cancer1
1RecruitingTreatmentUnspecified Adult Solid Tumor, Protocol Specific1
1TerminatedTreatmentAdenocarcinomas / Esophageal Cancers / Neoplasms, Esophageal / Squamous Cell Carcinoma (SCC)1
1TerminatedTreatmentAdvanced Colorectal Cancer1
1TerminatedTreatmentAnal Cancer1
1TerminatedTreatmentDuct Cell Adenocarcinoma of the Pancreas / Stage III Pancreatic Cancer / Stage IV Pancreatic Cancer1
1TerminatedTreatmentMucinous Adenocarcinoma of the Rectum / Stage IIA Rectal Cancer / Stage IIB Rectal Cancer / Stage IIC Rectal Cancer / Stage IIIB Rectal Cancer / Stage IIIC Rectal Cancer1
1TerminatedTreatmentRecurrent Colon Cancer / Recurrent Rectal Cancer / Stage IV Colon Cancer / Stage IV Rectal Cancer1
1TerminatedTreatmentTumors, Solid1
1WithdrawnTreatmentHead and Neck Cancers / Lip and Oral Cavity Cancer / Oropharyngeal Cancers1
1WithdrawnTreatmentStage IVA Colorectal Cancer / Stage IVB Colorectal Cancer1
1, 2Active Not RecruitingTreatmentAdenocarcinoma of the Esophagus / Adenocarcinomas of the Gastroesophageal Junction / Diffuse Adenocarcinoma of the Stomach / Intestinal Adenocarcinoma of the Stomach / Mixed Adenocarcinoma of the Stomach / Recurrent Esophageal Cancer / Recurrent Gastric Cancer / Stage IV Esophageal Cancer / Stage IV Gastric Cancer1
1, 2Active Not RecruitingTreatmentAdenocarcinoma of the Pancreas / Pancreatic Cancers1
1, 2Active Not RecruitingTreatmentCancer, Breast1
1, 2Active Not RecruitingTreatmentColorectal Cancers1
1, 2Active Not RecruitingTreatmentEsophageal Cancers3
1, 2Active Not RecruitingTreatmentGastric Cancers / Unspecified Adult Solid Tumor, Protocol Specific1
1, 2Active Not RecruitingTreatmentOropharynx Cancers / Squamous Cell Carcinoma of the Oral Cavity1
1, 2Active Not RecruitingTreatmentStage IV Pancreatic Cancer1
1, 2CompletedTreatmentAdenocarcinoma of the Rectum / Rectal Cancers1
1, 2CompletedTreatmentAdenocarcinoma of the Rectum / Stage II Rectal Cancer / Stage III Rectal Cancer1
1, 2CompletedTreatmentAdvanced Squamous Cell Carcinoma / Squamous Cell Carcinoma of Head and Neck / SSCHN1
1, 2CompletedTreatmentCarcinoma of Head and/or Neck / Squamous Cell Carcinoma (SCC)1
1, 2CompletedTreatmentCarcinoma of Unknown Primary / Head and Neck Cancers1
1, 2CompletedTreatmentCervical Cancers1
1, 2CompletedTreatmentColorectal Cancers6
1, 2CompletedTreatmentColorectal Cancers / Kidney Cancer1
1, 2CompletedTreatmentEsophageal Cancers3
1, 2CompletedTreatmentGastroEsophageal Cancer / Malignant Solid Tumours1
1, 2CompletedTreatmentGastrointestinal Diseases1
1, 2CompletedTreatmentHead and Neck Cancers4
1, 2CompletedTreatmentHepatocellular Carcinomas1
1, 2CompletedTreatmentKidney Cancer1
1, 2CompletedTreatmentMetastatic Colorectal Cancers1
1, 2CompletedTreatmentNeoplasms Metastasis / Neoplasms, Gastrointestinal1
1, 2CompletedTreatmentRecurrent Renal Cell Carcinoma / Stage IV Renal Cell Cancer1
1, 2CompletedTreatmentSquamous Cell Cancer1
1, 2Not Yet RecruitingTreatmentAdenocarcinoma of the Esophagus / Adenocarcinomas of the Gastroesophageal Junction / Diffuse Adenocarcinoma of the Stomach / Gastrointestinal Cancers / Intestinal Adenocarcinoma of the Stomach / Mixed Adenocarcinoma of the Stomach / Stage IIIA Esophageal Cancer / Stage IIIA Gastric Cancer / Stage IIIB Esophageal Cancer / Stage IIIB Gastric Cancer / Stage IIIC Esophageal Cancer / Stage IIIC Gastric Cancer / Stage IV Esophageal Cancer / Stage IV Gastric Cancer1
1, 2Not Yet RecruitingTreatmentColon Adenocarcinoma / Metastatic Pancreatic Adenocarcinoma / Pancreatic Adenocarcinoma / Pancreatic Ductal Adenocarcinoma / Rectal Adenocarcinoma / Stage III Pancreatic Cancer / Stage IIIA Colon Cancer / Stage IIIA Rectal Cancer / Stage IIIB Colon Cancer / Stage IIIB Rectal Cancer / Stage IIIC Colon Cancer / Stage IIIC Rectal Cancer / Stage IV Pancreatic Cancer / Stage IVA Colon Cancer / Stage IVA Rectal Cancer / Stage IVB Colon Cancer / Stage IVB Rectal Cancer1
1, 2RecruitingTreatmentAdenocarcinoma of Unknown Primary / Adult Cholangiocarcinoma / Gallbladder Carcinoma / Gastric Adenocarcinoma / Malignant Gastrointestinal Neoplasm / Metastatic Pancreatic Adenocarcinoma / Pancreatic Adenocarcinoma / Stage III Ampulla of Vater Cancer / Stage III Pancreatic Cancer / Stage IIIA Gallbladder Cancer / Stage IIIA Gastric Cancer / Stage IIIB Gallbladder Cancer / Stage IIIB Gastric Cancer / Stage IV Ampulla of Vater Cancer / Stage IV Gallbladder Cancer / Stage IV Gastric Cancer / Stage IV Pancreatic Cancer1
1, 2RecruitingTreatmentAdenocarcinomas / Colon Cancer / Metastasis / Rectal Cancers1
1, 2RecruitingTreatmentEsophageal Cancers1
1, 2RecruitingTreatmentMetastatic Pancreatic Adenocarcinoma1
1, 2RecruitingTreatmentNeoplasms, Colorectal1
1, 2RecruitingTreatmentPancreatic Cancer Metastatic1
1, 2RecruitingTreatmentRectal Cancers2
1, 2SuspendedTreatmentHead and Neck Squamous Cell Carcinoma (HNSCC) / Human Papillomavirus Infections / Salivary Gland Squamous Cell Carcinoma / Stage IVA Hypopharyngeal Squamous Cell Carcinoma / Stage IVA Laryngeal Squamous Cell Carcinoma / Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma / Stage IVA Major Salivary Gland Carcinoma / Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma / Stage IVA Oropharyngeal Carcinoma / Stage IVA Oropharyngeal Squamous Cell Carcinoma / Stage IVB Hypopharyngeal Squamous Cell Carcinoma / Stage IVB Laryngeal Squamous Cell Carcinoma / Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma / Stage IVB Major Salivary Gland Carcinoma / Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma / Stage IVB Oropharyngeal Carcinoma / Stage IVB Oropharyngeal Squamous Cell Carcinoma / Tongue Carcinoma1
1, 2SuspendedTreatmentMetastatic Pancreatic Adenocarcinoma / Recurrent Pancreatic Carcinoma / Stage III Pancreatic Cancer / Stage IV Pancreatic Cancer1
1, 2TerminatedTreatmentAdenocarcinoma of the Esophagus / Adenocarcinomas of the Gastroesophageal Junction / Diffuse Adenocarcinoma of the Stomach / Intestinal Adenocarcinoma of the Stomach / Mixed Adenocarcinoma of the Stomach / Recurrent Esophageal Cancer / Recurrent Gastric Cancer / Squamous Cell Carcinoma of the Esophagus / Stage III Esophageal Cancer / Stage IIIA Gastric Cancer / Stage IIIB Gastric Cancer / Stage IIIC Gastric Cancer / Stage IV Esophageal Cancer / Stage IV Gastric Cancer1
1, 2TerminatedTreatmentMucinous Adenocarcinoma of the Colon / Mucinous Adenocarcinoma of the Rectum / Recurrent Colon Cancer / Recurrent Rectal Cancer / Signet Ring Adenocarcinoma of the Colon / Signet Ring Adenocarcinoma of the Rectum / Stage IVA Colon Cancer / Stage IVA Rectal Cancer / Stage IVB Colon Cancer / Stage IVB Rectal Cancer1
1, 2TerminatedTreatmentNeoplasms1
1, 2TerminatedTreatmentPancreatic Cancers1
1, 2TerminatedTreatmentPancreatic Cancers / Pancreatic Ductal Adenocarcinoma1
1, 2TerminatedTreatmentStage II Rectal Cancer / Stage III Rectal Cancer1
1, 2TerminatedTreatmentSubjects With Resectable Local or Locally Advanced, Non-Metastatic (T2-T4, N0-N3, M0; Stages II and III) and Histologically-Confirmed Intestinal GC1
1, 2WithdrawnTreatmentColorectal Cancers1
1, 2WithdrawnTreatmentPancreatic Cancers1
2Active Not RecruitingTreatmentAdenocarcinoma of the Esophagus / Adenocarcinomas of the Gastroesophageal Junction / Diffuse Adenocarcinoma of the Stomach / Intestinal Adenocarcinoma of the Stomach / Mixed Adenocarcinoma of the Stomach / Squamous Cell Carcinoma of the Esophagus / Stage IA Esophageal Cancer / Stage IA Gastric Cancer / Stage IB Esophageal Cancer / Stage IB Gastric Cancer / Stage IIA Esophageal Cancer / Stage IIA Gastric Cancer / Stage IIB Esophageal Cancer / Stage IIB Gastric Cancer / Stage IIIA Esophageal Cancer / Stage IIIA Gastric Cancer / Stage IIIB Esophageal Cancer / Stage IIIB Gastric Cancer / Stage IIIC Esophageal Cancer / Stage IIIC Gastric Cancer1
2Active Not RecruitingTreatmentAdenocarcinomas of the Gastroesophageal Junction / Esophageal Cancers1
2Active Not RecruitingTreatmentAdenocarcinomas of the Gastroesophageal Junction / Esophageal Cancers / Gastric Cancers2
2Active Not RecruitingTreatmentAdult Cholangiocarcinoma / Advanced Adult Hepatocellular Carcinoma / BCLC Stage C Adult Hepatocellular Carcinoma / BCLC Stage D Adult Hepatocellular Carcinoma / Hilar Cholangiocarcinoma / Localized Non-Resectable Adult Liver Carcinoma / Recurrent Adult Liver Carcinoma / Recurrent Childhood Liver Cancer / Recurrent Extrahepatic Bile Duct Carcinoma / Recurrent Gallbladder Carcinoma / Stage II Gallbladder Cancer / Stage III Childhood Hepatocellular Carcinoma / Stage IIIA Gallbladder Cancer / Stage IIIB Gallbladder Cancer / Stage IV Childhood Hepatocellular Carcinoma / Stage IV Distal Bile Duct Cancer / Stage IVA Gallbladder Cancer / Stage IVB Gallbladder Cancer / Unresectable Extrahepatic Bile Duct Carcinoma1
2Active Not RecruitingTreatmentAdult Primary Cholangiocellular Carcinoma / Advanced Adult Primary Liver Cancer / Cholangiocarcinoma of the Extrahepatic Bile Duct / Cholangiocarcinoma of the Gallbladder / Localized Unresectable Adult Primary Liver Cancer / Periampullary Adenocarcinoma / Recurrent Adult Primary Liver Cancer / Recurrent Extrahepatic Bile Duct Cancer / Recurrent Gallbladder Cancer / Unresectable Extrahepatic Bile Duct Cancer / Unresectable Gallbladder Cancer1
2Active Not RecruitingTreatmentAnal Cancer3
2Active Not RecruitingTreatmentBiliary Cancer / Pancreatic Cancers1
2Active Not RecruitingTreatmentBladder Cancers2
2Active Not RecruitingTreatmentBladder Cancers / Transitional Cell Cancer of the Renal Pelvis and Ureter / Urethral Cancer1
2Active Not RecruitingTreatmentBladder Cancers / Urachal Cancer / Urethral Cancer1
2Active Not RecruitingTreatmentCancer (Advanced Stage)1
2Active Not RecruitingTreatmentCancer, Breast11
2Active Not RecruitingTreatmentCancer, Ovarian1
2Active Not RecruitingTreatmentCarcinoma of the Appendix / Colorectal Cancers / Primary Peritoneal Cavity Cancer1
2Active Not RecruitingTreatmentCarcinoma, Squamous Cell of Head and Neck1
2Active Not RecruitingTreatmentChemoradiation / Neoplasms, Esophageal1
2Active Not RecruitingTreatmentColorectal Cancers13
2Active Not RecruitingTreatmentColorectal Cancers / Metastatic Cancers5
2Active Not RecruitingTreatmentColorectal Cancers / Metastatic Cancers / Primary Peritoneal Cavity Cancer1
2Active Not RecruitingTreatmentEsophageal Cancers4
2Active Not RecruitingTreatmentEsophageal Cancers / Gastric Cancers3
2Active Not RecruitingTreatmentExtrahepatic Bile Duct Cancer / Gastric Cancers / Gastrointestinal Carcinoid Tumor / Liver Cancer / Pancreatic Cancers / Small Intestine Cancer1
2Active Not RecruitingTreatmentExtrahepatic Bile Duct Cancer / Pancreatic Cancers1
2Active Not RecruitingTreatmentGastric Adenocarcinoma With Peritoneal Carcinomatosis / Siewert Type II Adenocarcinoma of Esophagogastric Junction With Peritoneal Carcinomatosis / Siewert Type III Adenocarcinoma of Esophagogastric Junction With Peritoneal Carcinomatosis1
2Active Not RecruitingTreatmentGastrointestinal Carcinoid Tumor / Islet Cell Tumor / Neoplastic Syndrome1
2Active Not RecruitingTreatmentHead and Neck Cancers7
2Active Not RecruitingTreatmentHead and Neck Squamous Cell Carcinoma (HNSCC)1
2Active Not RecruitingTreatmentHepatocellular Carcinomas / Portal Vein Tumor Thrombus1
2Active Not RecruitingTreatmentKidney Cancer1
2Active Not RecruitingTreatmentMetastatic Cancers / Pancreatic Cancers1
2Active Not RecruitingTreatmentMetastatic Colorectal Cancers1
2Active Not RecruitingTreatmentMetastatic Pancreatic Adenocarcinoma1
2Active Not RecruitingTreatmentNasopharyngeal Carcinoma1
2Active Not RecruitingTreatmentNeoplasms, Colorectal1
2Active Not RecruitingTreatmentNeoplasms, Head and Neck1
2Active Not RecruitingTreatmentPancreatic Adenocarcinoma / Poorly Differentiated Malignant Neoplasm / Resectable Pancreatic Cancers / Stage IA Pancreatic Cancer / Stage IB Pancreatic Cancer / Stage IIA Pancreatic Cancer / Stage IIB Pancreatic Cancer / Stage III Pancreatic Cancer / Undifferentiated Pancreatic Carcinoma1
2Active Not RecruitingTreatmentPancreatic Cancers7
2Active Not RecruitingTreatmentRectal Adenocarcinoma / Stage II Rectal Cancer / Stage III Rectal Cancer1
2Active Not RecruitingTreatmentRectal Cancers2
2Active Not RecruitingTreatmentSquamous Cell Carcinoma of the Head and Neck (SCCHN)1
2Active Not RecruitingTreatmentTumors, Solid1
2AvailableNot AvailableHepatocellular Carcinomas / Injury; Blood Vessel, Hepatic, Artery1
2CompletedNot AvailableCancer, Breast1
2CompletedDiagnosticUpper Gastrointestinal Tumours1
2CompletedSupportive CareColorectal Cancers1
2CompletedSupportive CareColorectal Cancers / Nausea and Vomiting1
2CompletedTreatmentAbdominal Neoplasms / Colonic Neoplasms / Mesothelioma / Peritoneal Neoplasms1
2CompletedTreatmentAdenocarcinoma Of Esophagus / Adenocarcinoma of GE Junction / Adenocarcinoma of Stomach1
2CompletedTreatmentAdenocarcinoma of Colon / Adenocarcinoma of Rectum / Metastatic Disease1
2CompletedTreatmentAdenocarcinoma of the Colon / Adenocarcinoma of the Rectum / Advanced Colorectal Cancer1
2CompletedTreatmentAdenocarcinoma of the Colon / Adenocarcinoma of the Rectum / Recurrent Colon Cancer / Recurrent Rectal Cancer / Stage IV Colon Cancer / Stage IV Rectal Cancer1
2CompletedTreatmentAdenocarcinoma of the Pancreas / Stage II Pancreatic Cancer / Stage III Pancreatic Cancer1
2CompletedTreatmentAdenocarcinoma of the Pancreas / Stage III Pancreatic Cancer / Stage IVA Pancreatic Cancer1
2CompletedTreatmentAdenocarcinoma of the Rectum / Mucinous Adenocarcinoma of the Colon / Recurrent Colon Cancer / Recurrent Rectal Cancer / Signet Ring Adenocarcinoma of the Colon / Stage IV Colon Cancer / Stage IV Rectal Cancer1
2CompletedTreatmentAdenocarcinoma of the Stomach / Adenocarcinomas of the Gastroesophageal Junction / Recurrent Gastric Cancer / Stage IIIA Gastric Cancer / Stage IIIB Gastric Cancer / Stage IIIC Gastric Cancer / Stage IV Gastric Cancer1
2CompletedTreatmentAdenocarcinomas of the Esophagogastric Junction / Gastric Cancers2
2CompletedTreatmentAdenocarcinomas / Neoplasms, Esophageal / Stomach Neoplasms1
2CompletedTreatmentBladder Cancers / Transitional Cell Cancer of the Renal Pelvis and Ureter / Urethral Cancer1
2CompletedTreatmentCancer of the Larynx / Cancer of the Oral Cavity / Cancer of the Pharynx / Head and Neck Cancers / Nose Neoplasms / Paranasal Sinus Neoplasms1
2CompletedTreatmentCancer of the Rectum / Colorectal Cancers / Rectal Cancers1
2CompletedTreatmentCancer, Breast3
2CompletedTreatmentCancer, Breast / Neoplasms, Breast1
2CompletedTreatmentCancers / Colon Cancer / Colorectal Cancers / Metastatic Cancers / Metastatic Colorectal Cancers / Rectal Cancers1
2CompletedTreatmentCarcinoma of Esophagus1
2CompletedTreatmentCarcinoma of Head/Neck / Squamous Cell Carcinoma (SCC)1
2CompletedTreatmentCarcinoma of Unknown Primary / Colorectal Cancers / Unspecified Adult Solid Tumor, Protocol Specific / Unspecified Childhood Solid Tumor, Protocol Specific1
2CompletedTreatmentCarcinoma, Colorectal2
2CompletedTreatmentCarcinomas / Nasopharyngeal Neoplasms1
2CompletedTreatmentColon Cancer1
2CompletedTreatmentColon Cancer / Rectal Cancers1
2CompletedTreatmentColorectal Cancer (CRC)1
2CompletedTreatmentColorectal Cancers38
2CompletedTreatmentColorectal Cancers / Liver Metastases2
2CompletedTreatmentColorectal Cancers / Metastatic Cancers6
2CompletedTreatmentColorectal Cancers / Neoplasms, Colorectal1
2CompletedTreatmentEndometrial Cancers1
2CompletedTreatmentEsophageal Adenocarcinomas / Gastric Adenocarcinoma1
2CompletedTreatmentEsophageal Cancers6
2CompletedTreatmentEsophageal Cancers / Gastric Cancers5
2CompletedTreatmentEsophageal Cancers / GastroEsophageal Cancer1
2CompletedTreatmentEsophageal Cancers / Head and Neck Cancers1
2CompletedTreatmentEsophageal Cancers / Squamous Cell Carcinoma (SCC)1
2CompletedTreatmentEsophageal Cancers / Stomach Cancer1
2CompletedTreatmentEsophageal Carcinoma1
2CompletedTreatmentEsophagus Cancer1
2CompletedTreatmentExtrahepatic Bile Duct Cancer / Gallbladder Cancer / Liver Cancer1
2CompletedTreatmentGastric Adenocarcinoma1
2CompletedTreatmentGastric Adenocarcinoma / Gastric Cancers1
2CompletedTreatmentGastric Cancers9
2CompletedTreatmentGastric Cancers / GastroEsophageal Cancer1
2CompletedTreatmentGastric Cancers / Stomach Cancer2
2CompletedTreatmentGastric cancer stage IV2
2CompletedTreatmentGastrointestinal Cancer Metastatic / Non Small Cell Lung Cancer Metastatic / Renal Cell Cancer Metastatic1
2CompletedTreatmentGastrointestinal Carcinoid Tumor / Lung Cancers1
2CompletedTreatmentHead and Neck Cancers10
2CompletedTreatmentHead and Neck Cancers / Oral Complications of Radiation Therapy / Radiation Toxicity1
2CompletedTreatmentHead and Neck Squamous Cell Carcinoma (HNSCC)2
2CompletedTreatmentHepatocellular Carcinomas1
2CompletedTreatmentIndividualized Chemotherapy1
2CompletedTreatmentLiver Cancer / Pancreatic Cancers1
2CompletedTreatmentLymphoma NOS1
2CompletedTreatmentMetastatic Adenocarcinoma of Gastric Cardia / Metastatic Adenocarcinoma of the Esophagus / Unresectable Adenocarcinoma of Gastric Cardia / Unresectable Adenocarcinoma of the Esophagus1
2CompletedTreatmentMetastatic Breast Cancer (MBC)1
2CompletedTreatmentMetastatic Colorectal Cancers5
2CompletedTreatmentNasopharyngeal Carcinoma1
2CompletedTreatmentNasopharyngeal Neoplasms1
2CompletedTreatmentNeoplasms Metastasis / Neoplasms, Colorectal1
2CompletedTreatmentNeoplasms, Breast1
2CompletedTreatmentNeoplasms, Colorectal2
2CompletedTreatmentNeoplasms, Esophageal1
2CompletedTreatmentNeoplasms, Esophageal / Stomach Neoplasms2
2CompletedTreatmentNeuroendocrine Carcinoma of the Skin1
2CompletedTreatmentPancreatic Acinar Cell Carcinoma / Pancreatic Ductal Adenocarcinoma / Recurrent Pancreatic Carcinoma / Stage IV Pancreatic Cancer1
2CompletedTreatmentPancreatic Cancer Metastatic1
2CompletedTreatmentPancreatic Cancers12
2CompletedTreatmentRectal Adenocarcinoma1
2CompletedTreatmentRectal Cancers4
2CompletedTreatmentRectal Carcinoma1
2CompletedTreatmentRectal Neoplasms1
2CompletedTreatmentRecurrent Extragonadal Seminoma / Recurrent Malignant Extragonadal Germ Cell Tumor / Recurrent Malignant Extragonadal Non-Seminomatous Germ Cell Tumor / Recurrent Malignant Testicular Germ Cell Tumor / Recurrent Ovarian Germ Cell Tumor / Stage III Testicular Cancer / Stage IV Extragonadal Non-Seminomatous Germ Cell Tumor / Stage IV Extragonadal Seminoma / Stage IV Ovarian Germ Cell Tumor1
2CompletedTreatmentSquamous Cell Carcinoma of the Head and Neck (SCCHN)1
2CompletedTreatmentSquamous Neck Carcinoma of the Head and Neck Cancer (SCCHN)1
2CompletedTreatmentStage II Squamous Cell Carcinoma of the Nasopharynx / Stage III Lymphoepithelioma of the Nasopharynx / Stage III Squamous Cell Carcinoma of the Nasopharynx / Stage IV Lymphoepithelioma of the Nasopharynx / Stage IV Squamous Cell Carcinoma of the Nasopharynx1
2CompletedTreatmentStomach Neoplasms2
2CompletedTreatmentTransitional Cell Carcinoma1
2CompletedTreatmentUnresectable Biliary Tract Cancer1
2Not Yet RecruitingTreatmentAdenocarcinoma of the Colon / Adenocarcinoma of the Rectum1
2Not Yet RecruitingTreatmentChildren / Nasopharyngeal Carcinoma1
2Not Yet RecruitingTreatmentColorectal Adenocarcinoma / Stage IVA Colorectal Cancer / Stage IVB Colorectal Cancer1
2Not Yet RecruitingTreatmentColorectal Cancers1
2Not Yet RecruitingTreatmentNasopharyngeal Carcinoma2
2Not Yet RecruitingTreatmentRectal Adenocarcinoma1
2Not Yet RecruitingTreatmentStage II Breast Cancer / Stage III Breast Cancer1
2Not Yet RecruitingTreatmentStomach Neoplasms1
2RecruitingDiagnosticColorectal Cancers1
2RecruitingPreventionGastric cancer stage IV1
2RecruitingTreatmentAcinar Cell Adenocarcinoma of the Pancreas / Duct Cell Adenocarcinoma of the Pancreas / Recurrent Pancreatic Cancer / Stage IV Pancreatic Cancer1
2RecruitingTreatmentAcinar Cell Adenocarcinoma of the Pancreas / Duct Cell Adenocarcinoma of the Pancreas / Stage I Pancreatic Cancer / Stage IIA Pancreatic Cancer / Stage IIB Pancreatic Cancer1
2RecruitingTreatmentAdenocarcinoma of Ampulla / Ductal Adenocarcinoma of Pancreas1
2RecruitingTreatmentAdenocarcinoma of the Esophagus / Adenocarcinoma of the Gastric Cardia / Adenocarcinomas of the Gastroesophageal Junction / Stage IIIA Esophageal Cancer / Stage IIIB Esophageal Cancer / Stage IIIC Esophageal Cancer1
2RecruitingTreatmentAdenocarcinoma of the Esophagus / Adenocarcinomas of the Gastroesophageal Junction / Stage II Esophageal Cancer1
2RecruitingTreatmentAdenocarcinomas of the Esophagogastric Junction1
2RecruitingTreatmentAdenocarcinomas of the Gastroesophageal Junction / Gastric Adenocarcinoma / Gastric Cancers1
2RecruitingTreatmentAdenocarcinomas of the Gastroesophageal Junction / Gastric Cancers1
2RecruitingTreatmentAdenocarincoma of Pancreas / Stage III Pancreatic Cancer / Stage IVA Pancreatic Cancer / Stage IVB Pancreatic Cancer1
2RecruitingTreatmentAdvanced Esophageal Carcinoma1
2RecruitingTreatmentAfter Resection of Liver Metastases / Colorectal Cancers / KRAS Wildtype1
2RecruitingTreatmentAnal Basaloid Carcinoma / Anal Canal Cloacogenic Carcinoma / Anal Squamous Cell Carcinoma / Metastatic Anal Canal Carcinoma / Recurrent Anal Canal Carcinoma / Stage IIIB Anal Canal Cancer / Stage IV Anal Canal Cancer1
2RecruitingTreatmentAnal Canal Carcinoma1
2RecruitingTreatmentAnal Cancer1
2RecruitingTreatmentBiliary Tract Cancer2
2RecruitingTreatmentBladder Cancers1
2RecruitingTreatmentBorderline Resectable Pancreatic Cancer1
2RecruitingTreatmentCancer, Breast2
2RecruitingTreatmentCancer, Breast / Cancer, Ovarian / Cervical Cancers / Endometrial Cancers1
2RecruitingTreatmentCancers2
2RecruitingTreatmentCarcinoma, Colorectal1
2RecruitingTreatmentCarcinoma, Squamous Cell of Head and Neck1
2RecruitingTreatmentChemotherapeutic Agent Toxicity / Colorectal Cancers / Neurotoxicity1
2RecruitingTreatmentColon Cancer1
2RecruitingTreatmentColorectal Cancers11
2RecruitingTreatmentColorectal Cancers / Metastatic Cancers1
2RecruitingTreatmentColorectal Cancers / Peritoneal Cavity Cancer1
2RecruitingTreatmentDeep Regional Hyperthermia / Hyperthermia / Hyperthermic Chemoradiotherapy / Hyperthermic Radiochemotherapy / Locally Advanced Rectal Cancer / Rectal Cancers1
2RecruitingTreatmentDocetaxel, Oxaliplatin and Fluorouracil1
2RecruitingTreatmentEsophageal Cancers1
2RecruitingTreatmentEsophageal Cancers / Gastric Cancers1
2RecruitingTreatmentEsophageal Squamous Cell Carcinomas2
2RecruitingTreatmentGastric Adenocarcinoma / Gastroesophageal Junction Adenocarcinoma1
2RecruitingTreatmentGastric Cancers / Gastroesophageal Junction Adenocarcinoma1
2RecruitingTreatmentGastric Caner1
2RecruitingTreatmentGastric Junction Adenocarcinoma / Gastroesophageal Junction Adenocarcinoma1
2RecruitingTreatmentHER2-positive Breast Cancer1
2RecruitingTreatmentHead and Neck Cancers1
2RecruitingTreatmentHepatocellular Cancer1
2RecruitingTreatmentHepatocellular Carcinoma Non-resectable1
2RecruitingTreatmentHepatocellular Carcinomas2
2RecruitingTreatmentHuman Papilloma Virus Infection / Stage III Squamous Cell Carcinoma of the Oropharynx / Stage IVA Squamous Cell Carcinoma of the Oropharynx / Stage IVB Squamous Cell Carcinoma of the Oropharynx1
2RecruitingTreatmentIncurable Colorectal Cancer / RAS-wild-type1
2RecruitingTreatmentLiver Cancer1
2RecruitingTreatmentLiver Only Metastasis From KRAS Exon 2 Wild Type (Under Protocol 1.0-1.2 Edition) and RAS Wild Type (Under Protocol 2.0 Edition) Colorectal Cancer1
2RecruitingTreatmentLocalized Squamous Cell Carcinoma of the Esophagus1
2RecruitingTreatmentMetastatic Breast Cancer (MBC)2
2RecruitingTreatmentMetastatic Colorectal Cancers11
2RecruitingTreatmentMetastatic Pancreatic Adenocarcinoma / Recurrent Pancreatic Carcinoma / Stage IV Pancreatic Cancer1
2RecruitingTreatmentMucinous Adenocarcinoma of the Colon / Mucinous Adenocarcinoma of the Rectum / Recurrent Colon Cancer / Recurrent Rectal Cancer / Signet Ring Adenocarcinoma of the Colon / Signet Ring Adenocarcinoma of the Rectum / Stage IV Colon Cancer / Stage IV Rectal Cancer1
2RecruitingTreatmentMucinous Adenocarcinoma of the Colon / Mucinous Adenocarcinoma of the Rectum / Signet Ring Adenocarcinoma of the Colon / Signet Ring Adenocarcinoma of the Rectum / Stage IV Colon Cancer / Stage IV Rectal Cancer1
2RecruitingTreatmentMucinous Adenocarcinoma of the Rectum / Signet Ring Adenocarcinoma of the Rectum / Stage IIA Rectal Cancer / Stage IIB Rectal Cancer / Stage IIC Rectal Cancer / Stage IIIA Rectal Cancer / Stage IIIB Rectal Cancer / Stage IIIC Rectal Cancer1
2RecruitingTreatmentNasopharyngeal Carcinoma4
2RecruitingTreatmentNeoplasms, Breast1
2RecruitingTreatmentNeoplasms, Colorectal1
2RecruitingTreatmentNeoplasms, Esophageal1
2RecruitingTreatmentNeoplasms, Esophageal / Stomach Neoplasms1
2RecruitingTreatmentNeoplasms, Pancreatic1
2RecruitingTreatmentPancreatic Adenocarcinoma / Resectable Pancreatic Cancers2
2RecruitingTreatmentPancreatic Adenocarcinoma / Resectable Pancreatic Cancers / Stage IA Pancreatic Cancer / Stage IB Pancreatic Cancer / Stage IIA Pancreatic Cancer / Stage IIB Pancreatic Cancer / Stage III Pancreatic Cancer1
2RecruitingTreatmentPancreatic Adenocarcinoma / Stage IIA Pancreatic Cancer / Stage IIB Pancreatic Cancer / Stage III Pancreatic Cancer1
2RecruitingTreatmentPancreatic Cancer Metastatic1
2RecruitingTreatmentPancreatic Cancers3
2RecruitingTreatmentPancreatic Cancers / Pancreatic Carcinoma Non-resectable1
2RecruitingTreatmentPancreatic Metastatic Cancer / Toxicity1
2RecruitingTreatmentParanasal Sinus Neoplasms / Squamous Cell Carcinoma (SCC)1
2RecruitingTreatmentRectal Adenocarcinoma / Stage II Rectal Cancer / Stage III Rectal Cancer1
2RecruitingTreatmentRectal Cancers4
2RecruitingTreatmentRecurrent Colorectal Carcinoma / Stage IVA Colorectal Cancer / Stage IVB Colorectal Cancer1
2RecruitingTreatmentResectable Pancreatic Ductal Adenocarcinoma1
2RecruitingTreatmentSinonasal Tumors1
2RecruitingTreatmentSquamous Cell Carcinoma (SCC) / Squamous Cell Carcinoma of Skin1
2RecruitingTreatmentSquamous Cell Carcinoma of the Anus1
2RecruitingTreatmentSquamous Cell Carcinoma of the Hypopharynx Stage III / Squamous Cell Carcinoma of the Hypopharynx Stage IV / Squamous Cell Carcinoma of the Larynx Stage III / Squamous Cell Carcinoma of the Larynx Stage IV / Squamous Cell Carcinoma of the Oral Cavity Stage III / Squamous Cell Carcinoma of the Oral Cavity Stage IV / Squamous Cell Carcinoma of the Oropharynx Stage III / Squamous Cell Carcinoma of the Oropharynx Stage IV1
2RecruitingTreatmentStage II Lymphoepithelioma of the Nasopharynx / Stage II Squamous Cell Carcinoma of the Nasopharynx / Stage III Lymphoepithelioma of the Nasopharynx / Stage III Squamous Cell Carcinoma of the Nasopharynx / Stage IV Lymphoepithelioma of the Nasopharynx / Stage IV Squamous Cell Carcinoma of the Nasopharynx1
2RecruitingTreatmentUnresectable Sinonasal Tumors1
2RecruitingTreatmentUrothelial Carcinoma of the Bladder1
2TerminatedTreatmentAdenocarcinoma of Pancreas1
2TerminatedTreatmentAdenocarcinoma of the Colon / Adenocarcinoma of the Rectum / Mucinous Adenocarcinoma of the Colon / Mucinous Adenocarcinoma of the Rectum / Recurrent Colon Cancer / Recurrent Rectal Cancer / Signet Ring Adenocarcinoma of the Colon / Signet Ring Adenocarcinoma of the Rectum / Stage IV Colon Cancer / Stage IV Rectal Cancer1
2TerminatedTreatmentAdenocarcinoma of the Distal Esophagus / Adenocarcinoma of the Proximal Stomach / Adenocarcinomas of the Gastroesophageal Junction / Gastroesophageal Adenocarcinoma1
2TerminatedTreatmentAdenocarcinoma of the Esophagus / Esophageal Cancers / Squamous Cell Carcinoma (SCC)1
2TerminatedTreatmentAdenocarcinomas of the Gastroesophageal Junction / Gastric Cancers1
2TerminatedTreatmentBile Duct Cancer / Cancer of Gallbladder / Cholangiocarcinomas / Hepatobiliary Neoplasms / Liver Cancer1
2TerminatedTreatmentBladder Cancers1
2TerminatedTreatmentCancer of Larynx1
2TerminatedTreatmentCancer of the Bile Duct / Gallbladder Cancer1
2TerminatedTreatmentCancer, Breast2
2TerminatedTreatmentCancers1
2TerminatedTreatmentColon Cancer1
2TerminatedTreatmentColorectal Cancers6
2TerminatedTreatmentColorectal Cancers / Metastases1
2TerminatedTreatmentColorectal Cancers / Metastatic Cancers1
2TerminatedTreatmentColorectal Liver Metastases1
2TerminatedTreatmentDiarrhea / Neoplasms, Colorectal1
2TerminatedTreatmentEsophageal Cancers4
2TerminatedTreatmentEsophageal Diseases1
2TerminatedTreatmentExtrahepatic Bile Duct Cancer / Liver Cancer1
2TerminatedTreatmentGastric Cancers4
2TerminatedTreatmentHER2 Positive Esophagogastric Cancer1
2TerminatedTreatmentHead and Neck Cancers3
2TerminatedTreatmentLiver Metastases / Recurrent Colon Cancer / Recurrent Rectal Cancer / Stage IVA Colon Cancer / Stage IVA Rectal Cancer / Stage IVB Colon Cancer / Stage IVB Rectal Cancer1
2TerminatedTreatmentLoco-regional Esophageal Cancer1
2TerminatedTreatmentMetastatic Colorectal Cancers2
2TerminatedTreatmentNeoplasm Metastases / Neoplasms, Colorectal1
2TerminatedTreatmentNeoplasms Metastasis / Neoplasms, Colorectal1
2TerminatedTreatmentNeoplasms, Breast1
2TerminatedTreatmentNeoplasms, Colorectal2
2TerminatedTreatmentOral Cancers / Squamous Cell Carcinoma (SCC)1
2TerminatedTreatmentPancreatic Cancers3
2TerminatedTreatmentPeritoneal Neoplasms1
2TerminatedTreatmentRectal Cancers1
2TerminatedTreatmentRectal Neoplasms1
2TerminatedTreatmentStage IB Esophageal Adenocarcinoma / Stage IIA Esophageal Adenocarcinoma / Stage IIB Esophageal Adenocarcinoma / Stage IIIA Esophageal Adenocarcinoma / Stage IIIB Esophageal Adenocarcinoma / Stage IIIC Esophageal Adenocarcinoma1
2TerminatedTreatmentStage IV Colon Cancer / Stage IV Rectal Cancer1
2TerminatedTreatmentUterine Neoplasms1
2WithdrawnTreatmentAdenocarcinoma of the Colon / Adenocarcinoma of the Rectum / Recurrent Colon Cancer / Recurrent Rectal Cancer / Stage IVA Colon Cancer / Stage IVA Rectal Cancer / Stage IVB Colon Cancer / Stage IVB Rectal Cancer1
2WithdrawnTreatmentCancer of Head and Neck1
2WithdrawnTreatmentColorectal Cancers2
2WithdrawnTreatmentColorectal Cancers / Metastatic Cancers1
2WithdrawnTreatmentColorectal Cancers / Metastatic Colorectal Cancers1
2WithdrawnTreatmentEsophagogastric Cancer1
2WithdrawnTreatmentHead and Neck Cancers1
2WithdrawnTreatmentHepatocellular Carcinomas / Lung Metastasis1
2WithdrawnTreatmentHuman Papilloma Virus (HPV) / Squamous Cell Carcinoma of the Head and Neck (SCCHN)1
2WithdrawnTreatmentMetastatic Colorectal Cancers2
2WithdrawnTreatmentMucinous Adenocarcinoma of the Colon / Mucinous Adenocarcinoma of the Rectum / Recurrent Colon Cancer / Recurrent Rectal Cancer / Signet Ring Adenocarcinoma of the Colon / Signet Ring Adenocarcinoma of the Rectum / Stage IVA Colon Cancer / Stage IVA Rectal Cancer / Stage IVB Colon Cancer / Stage IVB Rectal Cancer1
2WithdrawnTreatmentNeoplasms, Colorectal1
2, 3Active Not RecruitingTreatmentColorectal Cancers3
2, 3Active Not RecruitingTreatmentGastric Cancers1
2, 3Active Not RecruitingTreatmentGastrointestinal Carcinoid Tumor / Islet Cell Tumor / Lung Cancers / Neoplastic Syndrome / Neuroendocrine Tumors1
2, 3Active Not RecruitingTreatmentPancreatic Cancers1
2, 3Active Not RecruitingTreatmentRectal Cancers1
2, 3CompletedDiagnosticColorectal Cancers1
2, 3CompletedTreatmentAdenocarcinomas / Esophageal Cancers1
2, 3CompletedTreatmentCisplatin Adverse Reaction / Upper GI Cancer1
2, 3CompletedTreatmentColorectal Cancers1
2, 3CompletedTreatmentEsophageal Cancers1
2, 3CompletedTreatmentGastric Cancers1
2, 3CompletedTreatmentNeoplasm Recurrence, Local / Neoplasms Metastasis / Neoplasms, Head and Neck1
2, 3CompletedTreatmentPancreatic Cancers2
2, 3Not Yet RecruitingTreatmentColorectal Cancers1
2, 3RecruitingTreatmentEpstein-Barr Virus Infections / Stage II Nasopharyngeal Carcinoma / Stage III Nasopharyngeal Carcinoma / Stage IVA Nasopharyngeal Carcinoma / Stage IVB Nasopharyngeal Carcinoma1
2, 3RecruitingTreatmentEsophageal Cancers1
2, 3RecruitingTreatmentRectal Cancers1
2, 3RecruitingTreatmentResectable Prancreas Carcinoma1
2, 3TerminatedTreatmentAnal Cancer1
2, 3WithdrawnTreatmentCarcinoma, Colorectal / Liver Metastases1
3Active Not RecruitingNot AvailableCancer, Breast1
3Active Not RecruitingTreatmentActinic Keratosis (AK) / Organ or Tissue Transplant; Complications1
3Active Not RecruitingTreatmentAnal Cancer1
3Active Not RecruitingTreatmentBreast Cancer Female1
3Active Not RecruitingTreatmentCancer of the Larynx / Cancer of the Nasal Cavity / Cancer of the Oral Cavity / Cancer of the Pharynx / Paranasal Sinus Neoplasms1
3Active Not RecruitingTreatmentCancer, Breast11
3Active Not RecruitingTreatmentCarcinoma of Unknown Primary2
3Active Not RecruitingTreatmentCognitive/Functional Effects / Colorectal Cancers / Neurotoxicity1
3Active Not RecruitingTreatmentColon Cancer / Metastatic Colorectal Cancers / Rectal Cancers1
3Active Not RecruitingTreatmentColon Mucinous Adenocarcinoma / Colon Signet Ring Cell Adenocarcinoma / Lynch Syndrome / Stage IIA Colon Cancer / Stage IIB Colon Cancer / Stage IIC Colon Cancer1
3Active Not RecruitingTreatmentColorectal Cancers19
3Active Not RecruitingTreatmentColorectal Cancers / Metastatic Cancers3
3Active Not RecruitingTreatmentColorectal Cancers / Neoplasms Metastasis1
3Active Not RecruitingTreatmentDigestive System Neoplasms / Intestinal Neoplasms / Neoplasms Metastasis / Neoplasms, Colorectal / Neoplasms, Gastrointestinal1
3Active Not RecruitingTreatmentEsophageal Cancers1
3Active Not RecruitingTreatmentEsophageal Cancers / Gastric Cancers2
3Active Not RecruitingTreatmentEsophageal Squamous Cell Cancer1
3Active Not RecruitingTreatmentHead and Neck Cancers4
3Active Not RecruitingTreatmentLocally Advanced Malignant Neoplasm / Pancreatic Cancers / Pancreatic Carcinoma Non-resectable1
3Active Not RecruitingTreatmentMetastatic Colorectal Cancers1
3Active Not RecruitingTreatmentNasopharyngeal Carcinoma3
3Active Not RecruitingTreatmentNasopharyngeal Neoplasms1
3Active Not RecruitingTreatmentNeoplasms, Head and Neck1
3Active Not RecruitingTreatmentPancreatic Cancers3
3Active Not RecruitingTreatmentRectal Neoplasms1
3Active Not RecruitingTreatmentRecurrent Hypopharyngeal Squamous Cell Carcinoma / Recurrent Laryngeal Squamous Cell Carcinoma / Recurrent Laryngeal Verrucous Carcinoma / Recurrent Lip and Oral Cavity Squamous Cell Carcinoma / Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary / Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma / Recurrent Oral Cavity Verrucous Carcinoma / Recurrent Oropharyngeal Squamous Cell Carcinoma / Recurrent Salivary Gland Carcinoma / Salivary Gland Squamous Cell Carcinoma / Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary / Stage IV Hypopharyngeal Squamous Cell Carcinoma / Stage IV Major Salivary Gland Carcinoma / Stage IVA Laryngeal Squamous Cell Carcinoma / Stage IVA Laryngeal Verrucous Carcinoma / Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma / Stage IVA Major Salivary Gland Carcinoma / Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma / Stage IVA Oral Cavity Verrucous Carcinoma / Stage IVA Oropharyngeal Squamous Cell Carcinoma / Stage IVB Laryngeal Squamous Cell Carcinoma / Stage IVB Laryngeal Verrucous Carcinoma / Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma / Stage IVB Major Salivary Gland Carcinoma / Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma / Stage IVB Oral Cavity Verrucous Carcinoma / Stage IVB Oropharyngeal Squamous Cell Carcinoma / Stage IVC Laryngeal Squamous Cell Carcinoma / Stage IVC Laryngeal Verrucous Carcinoma / Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma / Stage IVC Major Salivary Gland Carcinoma / Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma / Stage IVC Oral Cavity Verrucous Carcinoma / Stage IVC Oropharyngeal Squamous Cell Carcinoma / Tongue Carcinoma / Untreated Metastatic Squamous Cell Carcinoma to Neck With Occult Primary1
3Active Not RecruitingTreatmentStage I Lymphoepithelioma of the Nasopharynx / Stage I Squamous Cell Carcinoma of the Nasopharynx / Stage II Lymphoepithelioma of the Nasopharynx / Stage II Squamous Cell Carcinoma of the Nasopharynx / Stage III Lymphoepithelioma of the Nasopharynx / Stage III Squamous Cell Carcinoma of the Nasopharynx / Stage IV Lymphoepithelioma of the Nasopharynx / Stage IV Squamous Cell Carcinoma of the Nasopharynx1
3CompletedPreventionCervix, Dysplasia / Infection, Human Immunodeficiency Virus1
3CompletedSupportive CareCancer, Breast1
3CompletedTreatmentActinic Keratosis (AK)2
3CompletedTreatmentAdenocarcinoma of the Colon / Adenocarcinoma of the Rectum / Recurrent Colon Cancer / Recurrent Rectal Cancer / Stage III Colon Cancer / Stage III Rectal Cancer / Stage IV Colon Cancer / Stage IV Rectal Cancer1
3CompletedTreatmentAdenocarcinoma of the Colon / Adenocarcinoma of the Rectum / Recurrent Colon Cancer / Recurrent Rectal Cancer / Stage IV Colon Cancer / Stage IV Rectal Cancer1
3CompletedTreatmentAdenocarcinoma of the Colon / Stage IIA Colon Cancer / Stage IIB Colon Cancer / Stage IIC Colon Cancer / Stage IIIA Colon Cancer / Stage IIIB Colon Cancer / Stage IIIC Colon Cancer1
3CompletedTreatmentAdenocarcinoma of the Colon / Stage III Colon Cancer2
3CompletedTreatmentAdenocarcinoma of the Stomach / Adenocarcinomas of the Gastroesophageal Junction1
3CompletedTreatmentAdenocarcinomas1
3CompletedTreatmentAnal Cancer2
3CompletedTreatmentBladder Cancers1
3CompletedTreatmentCancer, Breast28
3CompletedTreatmentCancer, Breast / Chemotherapy, Adjuvant1
3CompletedTreatmentCervical Cancers2
3CompletedTreatmentChildhood Hepatoblastoma / Recurrent Childhood Liver Cancer / Stage I Childhood Liver Cancer1
3CompletedTreatmentColon Cancer Stage II1
3CompletedTreatmentColon Cancer Stage III1
3CompletedTreatmentColorectal Cancers30
3CompletedTreatmentColorectal Cancers / Metastasis1
3CompletedTreatmentColorectal Cancers / Metastatic Cancers3
3CompletedTreatmentColorectal Peritoneal Carcinomatosis1
3CompletedTreatmentDrug/Agent Toxicity by Tissue/Organ / Pancreatic Cancers1
3CompletedTreatmentEarly Stage Breast Cancer1
3CompletedTreatmentEarly-Stage Breast Cancer1
3CompletedTreatmentEpidermal Growth Factor Receptor (EGFR) Expressing Metastatic Colorectal Cancer1
3CompletedTreatmentEsophageal Cancers4
3CompletedTreatmentEsophageal Cancers / Gastric Cancers1
3CompletedTreatmentEsophagus Cancer1
3CompletedTreatmentGastric Cancers5
3CompletedTreatmentGlaucoma1
3CompletedTreatmentHead and Neck Cancers7
3CompletedTreatmentKidney Cancer2
3CompletedTreatmentMetastatic Colorectal Cancers3
3CompletedTreatmentMucinous Adenocarcinoma of the Colon / Mucinous Adenocarcinoma of the Rectum / Recurrent Colon Cancer / Recurrent Rectal Cancer / Signet Ring Adenocarcinoma of the Colon / Signet Ring Adenocarcinoma of the Rectum / Stage IIIA Colon Cancer / Stage IIIA Rectal Cancer / Stage IIIB Colon Cancer / Stage IIIB Rectal Cancer / Stage IIIC Colon Cancer / Stage IIIC Rectal Cancer / Stage IVA Colon Cancer / Stage IVA Rectal Cancer / Stage IVB Colon Cancer / Stage IVB Rectal Cancer1
3CompletedTreatmentNeoplasms Metastasis / Neoplasms, Colorectal1
3CompletedTreatmentNeoplasms, Pancreatic2
3CompletedTreatmentPancreatic Cancer Metastatic1
3CompletedTreatmentPancreatic Cancers6
3CompletedTreatmentRectal Cancers1
3CompletedTreatmentSquamous Cell Carcinoma of the Head and Neck (SCCHN)1
3CompletedTreatmentStage II Colon Cancer / Stage III Colon Cancer1
3CompletedTreatmentStomach Neoplasms1
3Not Yet RecruitingTreatmentGastric Cancers1
3RecruitingPreventionAnal Cancer / High-Grade Squamous Intraepithelial Lesions / Human Papilloma Virus Infection / Infection, Human Immunodeficiency Virus1
3RecruitingPreventionChemotherapy-Induced Neutropenia / Colorectal Cancers1
3RecruitingPreventionHigh-risk for Proliferative Vitreoretinopathy (PVR) / Rhegmatogenous Retinal Detachments1
3RecruitingTreatmentAdenocarcinomas of the Esophagogastric Junction / Esophageal Adenocarcinoma (UICC TNM7)1
3RecruitingTreatmentAmpullary Cancer / Biliary Tract Cancer / Cholangiocarcinomas / Gallbladder Cancer1
3RecruitingTreatmentAnal Carcinoma1
3RecruitingTreatmentAnal Intraepithelial Neoplasia (AIN) / High-Grade Squamous Intraepithelial Lesions / Infection, Human Immunodeficiency Virus1
3RecruitingTreatmentBRAF V600E-mutant Metastatic Colorectal Cancer1
3RecruitingTreatmentCRC1
3RecruitingTreatmentCancer, Breast2
3RecruitingTreatmentCancer, Breast / Cardiac Toxicity / Perioperative/Postoperative Complications1
3RecruitingTreatmentCarcinoma, Squamous Cell of Head and Neck1
3RecruitingTreatmentChalazion1
3RecruitingTreatmentColon Cancer1
3RecruitingTreatmentColorectal Cancers6
3RecruitingTreatmentColorectal Cancers / Metastatic Cancers1
3RecruitingTreatmentColorectal Cancers / Primary Peritoneal Cavity Cancer1
3RecruitingTreatmentEffects of Chemotherapy / General Surgery / Local Neoplasm Recurrences / Metastasis / Neoplasms, Colorectal1
3RecruitingTreatmentEsophageal Cancers1
3RecruitingTreatmentGastric Adenocarcinoma2
3RecruitingTreatmentGastric Cancers2
3RecruitingTreatmentGastric Cancers / Gastroesophageal Junction Cancer1
3RecruitingTreatmentGastroesophageal Junction Adenocarcinoma / Metastatic Gastric Adenocarcinoma1
3RecruitingTreatmentHead and Neck Cancers1
3RecruitingTreatmentHead and Neck Squamous Cell Cancer1
3RecruitingTreatmentHepatocellular Carcinomas1
3RecruitingTreatmentLocal Advanced Esophageal Squamous Cell Carcinoma1
3RecruitingTreatmentMetastatic Colorectal Cancers1
3RecruitingTreatmentMetastatic Head and Neck Cancer / Recurrent Head and Neck Cancer1
3RecruitingTreatmentMetastatic Pancreatic Adenocarcinoma1
3RecruitingTreatmentNasopharyngeal Carcinoma1
3RecruitingTreatmentPRETEXT Stage 1 Hepatoblastoma / PRETEXT Stage 2 Hepatoblastoma / PRETEXT Stage 3 Hepatoblastoma / PRETEXT Stage 4 Hepatoblastoma1
3RecruitingTreatmentPancreatic Acinar Cell Carcinoma / Pancreatic Ductal Adenocarcinoma / Pancreatic Intraductal Papillary-Mucinous Neoplasm / Stage IA Pancreatic Cancer / Stage IB Pancreatic Cancer / Stage IIA Pancreatic Cancer / Stage IIB Pancreatic Cancer1
3RecruitingTreatmentPancreatic Cancers1
3RecruitingTreatmentSquamous Cell Carcinoma of the Head and Neck (SCCHN)1
3RecruitingTreatmentStage ⅡA Pancreatic Cancer / Stage ⅡB Pancreatic Cancer1
3RecruitingTreatmentUnresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction1
3SuspendedTreatmentCancer, Breast1
3SuspendedTreatmentMetastatic Colorectal Cancers1
3TerminatedTreatmentAdenocarcinoma of the Colon / Adenocarcinoma of the Rectum / Recurrent Colon Cancer / Recurrent Rectal Cancer / Stage III Colon Cancer / Stage III Rectal Cancer / Stage IV Colon Cancer / Stage IV Rectal Cancer1
3TerminatedTreatmentAdenocarcinoma of the Rectum / Stage II Rectal Cancer / Stage III Rectal Cancer1
3TerminatedTreatmentCancer, Breast2
3TerminatedTreatmentColorectal Cancers1
3TerminatedTreatmentEsophageal Cancers1
3TerminatedTreatmentGastric Cancers1
3TerminatedTreatmentGastric Carcinoma Stage IV1
3TerminatedTreatmentHead and Neck Cancers2
3TerminatedTreatmentMucinous Adenocarcinoma of the Rectum / Recurrent Rectal Cancer / Signet Ring Adenocarcinoma of the Rectum / Stage IIA Rectal Cancer / Stage IIB Rectal Cancer / Stage IIC Rectal Cancer / Stage IIIA Rectal Cancer / Stage IIIB Rectal Cancer / Stage IIIC Rectal Cancer / Stage IVA Rectal Cancer / Stage IVB Rectal Cancer1
3TerminatedTreatmentNeoplasms Metastasis / Neoplasms, Pancreatic1
3TerminatedTreatmentNeoplasms, Esophageal / Squamous Cell Cancer1
3TerminatedTreatmentRecurrent Colon Cancer / Recurrent Rectal Cancer / Stage IVA Colon Cancer / Stage IVA Rectal Cancer / Stage IVB Colon Cancer / Stage IVB Rectal Cancer1
3WithdrawnTreatmentEsophageal Cancers1
3WithdrawnTreatmentHead and Neck Cancers1
3WithdrawnTreatmentHepatocellular Carcinomas1
3WithdrawnTreatmentLocalized Resectable Adult Primary Liver Cancer / Stage III Childhood Liver Cancer1
4Active Not RecruitingPreventionBasal Cell Carcinoma (BCC) / Carcinomas / Neoplasms, Basal Cell / Neoplasms, Squamous Cell / Skin Diseases / Skin Neoplasms / Squamous Cell Carcinoma (SCC)1
4CompletedTreatmentActinic Keratosis (AK)1
4CompletedTreatmentColorectal Cancers2
4CompletedTreatmentGlaucoma1
4CompletedTreatmentStage-Ⅱ Colorectal Cancer1
4Not Yet RecruitingTreatmentKeloidscars1
4Not Yet RecruitingTreatmentNeoadjuvant Therapy / Neoplasms, Breast1
4RecruitingTreatmentActinic Keratosis (AK)1
4RecruitingTreatmentAdvanced Adult Primary Liver Cancer1
4RecruitingTreatmentColorectal Cancers1
4RecruitingTreatmentEsophageal Adenocarcinomas / Gastric Adenocarcinoma / Stage IIB Gastric Cancer / Stage IIIA Esophageal Adenocarcinoma / Stage IIIA Gastric Cancer / Stage IIIB Esophageal Adenocarcinoma / Stage IIIB Gastric Cancer / Stage IIIC Esophageal Adenocarcinoma / Stage IIIC Gastric Cancer1
4RecruitingTreatmentNeoplasms Metastasis / Neoplasms, Colorectal / Neoplasms, Liver1
4TerminatedTreatmentPlantar Warts1
Not AvailableActive Not RecruitingTreatmentAcinar Cell Adenocarcinoma of the Pancreas / Duct Cell Adenocarcinoma of the Pancreas / Recurrent Pancreatic Cancer / Stage II Pancreatic Cancer / Stage III Pancreatic Cancer1
Not AvailableActive Not RecruitingTreatmentCancer, Breast1
Not AvailableActive Not RecruitingTreatmentCancer, Breast / Pregnancy1
Not AvailableActive Not RecruitingTreatmentHead and Neck Cancers1
Not AvailableActive Not RecruitingTreatmentNasopharyngeal Neoplasms / Squamous Cell Carcinoma (SCC)1
Not AvailableActive Not RecruitingTreatmentPancreatic Cancers2
Not AvailableApproved for MarketingNot AvailablePancreatic Cancers1
Not AvailableCompletedNot AvailableActinic Keratosis (AK)1
Not AvailableCompletedNot AvailableCervical Cancers1
Not AvailableCompletedDiagnosticEsophageal Cancers / Gastric Cancers1
Not AvailableCompletedSupportive CareExtrahepatic Bile Duct Cancer / Nausea / Stage II Pancreatic Cancer / Stage III Pancreatic Cancer / Stage IV Pancreatic Cancer / Vomiting1
Not AvailableCompletedTreatmentActinic Keratosis (AK)1
Not AvailableCompletedTreatmentCancer, Breast2
Not AvailableCompletedTreatmentColorectal Cancers3
Not AvailableCompletedTreatmentKeratosis / Photo-aging1
Not AvailableCompletedTreatmentMetastatic Colorectal Cancers1
Not AvailableCompletedTreatmentRectal Cancers1
Not AvailableNot Yet RecruitingHealth Services ResearchCancer, Breast1
Not AvailableNot Yet RecruitingTreatmentNasopharyngeal Neoplasms1
Not AvailableRecruitingNot AvailableColorectal Cancers1
Not AvailableRecruitingNot AvailableHepatocellular Carcinomas1
Not AvailableRecruitingTreatmentBleb1
Not AvailableRecruitingTreatmentCancer, Breast1
Not AvailableRecruitingTreatmentCarcinoma of the Anal Canal1
Not AvailableRecruitingTreatmentCervical Cancers / Uterine Cancers1
Not AvailableRecruitingTreatmentChemotherapy, Adjuvant / Hepatocellular Carcinomas / Survival / Transplantation, Liver / Tumor Recurrence and Metastasis1
Not AvailableRecruitingTreatmentColorectal Cancers / Liver Metastasis1
Not AvailableRecruitingTreatmentEsophageal Cancers1
Not AvailableRecruitingTreatmentEsophageal Cancers / Gastric Cancers1
Not AvailableRecruitingTreatmentLocalized Pancreas Cancer / Non-metastatic Pancreas Cancer / Pancreas Cancer1
Not AvailableRecruitingTreatmentMetastatic Colorectal Cancers1
Not AvailableRecruitingTreatmentNeoplasms1
Not AvailableRecruitingTreatmentPancreas Cancer1
Not AvailableRecruitingTreatmentPancreatitis,Acute Necrotizing1
Not AvailableTerminatedTreatmentNasopharyngeal Neoplasms / Squamous Cell Carcinoma (SCC)1
Not AvailableWithdrawnTreatmentCancer, Breast1
Not AvailableWithdrawnTreatmentRecurrent Colon Cancer / Recurrent Rectal Cancer / Stage IVA Colon Cancer / Stage IVA Rectal Cancer / Stage IVB Colon Cancer / Stage IVB Rectal Cancer1
PharmacodynamicsFluorouracil is an antineoplastic anti-metabolite. Anti-metabolites masquerade as purine or pyrimidine - which become the building blocks of DNA. They prevent these substances from becoming incorporated into DNA during the "S" phase (of the cell cycle), stopping normal development and division. Fluorouracil blocks an enzyme which converts the cytosine nucleotide into the deoxy derivative. In addition, DNA synthesis is further inhibited because Fluorouracil blocks the incorporation of the thymidine nucleotide into the DNA strand.
Mechanism of actionThe precise mechanism of action has not been fully determined, but the main mechanism of fluorouracil is thought to be the binding of the deoxyribonucleotide of the drug (FdUMP) and the folate cofactor, N5–10-methylenetetrahydrofolate, to thymidylate synthase (TS) to form a covalently bound ternary complex. This results in the inhibition of the formation of thymidylate from uracil, which leads to the inhibition of DNA and RNA synthesis and cell death. Fluorouracil can also be incorporated into RNA in place of uridine triphosphate (UTP), producing a fraudulent RNA and interfering with RNA processing and protein synthesis.
TargetKindPharmacological actionActionsOrganismUniProt ID
Thymidylate synthaseProteinyes
other/unknown
HumanP04818 details
DNANucleotideyes
incorporation into and destabilization
Humannot applicabledetails
RNANucleotideyes
incorporation into and destabilization
Humannot applicabledetails
Related Articles
Absorption28-100%
Volume of distributionNot Available
Protein binding8-12%
Metabolism

Hepatic. The catabolic metabolism of fluorouracil results in degradation products ( e.g., CO2, urea and α-fluoro-ß-alanine) which are inactive.

Route of eliminationSeven percent to 20% of the parent drug is excreted unchanged in the urine in 6 hours; of this over 90% is excreted in the first hour. The remaining percentage of the administered dose is metabolized, primarily in the liver.
Half life10-20 minutes
ClearanceNot Available
ToxicityLD50=230mg/kg (orally in mice)
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Fluorouracil Metabolism PathwayDrug metabolismSMP00608
Capecitabine Metabolism PathwayDrug metabolismSMP00607
Capecitabine Action PathwayDrug actionSMP00469
Fluorouracil Action PathwayDrug actionSMP00470
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug Reactions
Interacting Gene/EnzymeSNP RS IDAllele nameDefining changeAdverse ReactionReference(s)
Thymidylate synthase
Gene symbol: TYMS
UniProt: P04818
rs34743033 TSER*2Not AvailableNeutropenia, diarrhea16818689
Uridine 5'-monophosphate synthase
Gene symbol: UMPS
UniProt: P11172
rs1801019 Not AvailableC AlleleNeutropenia, diarrhea16818689
Dihydropyrimidine dehydrogenase [NADP(+)]
Gene symbol: DPYD
UniProt: Q12882
rs1801265 Not AvailableC alleleNausea, vomiting, reduced white cell count17848752
Dihydropyrimidine dehydrogenase [NADP(+)]
Gene symbol: DPYD
UniProt: Q12882
rs1801159 Not AvailableG alleleNausea, vomiting, reduced white cell count17848752
Glutathione S-transferase P
Gene symbol: GSTP1
UniProt: P09211
rs1695 Not AvailableA alleleHematological toxicity, gastrointestinal toxicity18540691
Dihydropyrimidine dehydrogenase [NADP(+)]
Gene symbol: DPYD
UniProt: Q12882
rs3918290 Not AvailableA alleleLeukopenia, diarrhea, mucositis18299612
Dihydropyrimidine dehydrogenase [NADP(+)]
Gene symbol: DPYD
UniProt: Q12882
rs67376798 Not AvailableT > APatients are at a higher risk of toxicity23603345
Interactions
Drug Interactions
DrugInteractionDrug group
AbirateroneThe serum concentration of Fluorouracil can be increased when it is combined with Abiraterone.Approved
AceclofenacThe metabolism of Aceclofenac can be decreased when combined with Fluorouracil.Approved
AcenocoumarolThe serum concentration of Acenocoumarol can be increased when it is combined with Fluorouracil.Approved
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Fluorouracil.Approved
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Fluorouracil.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Fluorouracil.Approved
Acetylsalicylic acidThe metabolism of Acetylsalicylic acid can be decreased when combined with Fluorouracil.Approved, Vet Approved
AlosetronThe metabolism of Alosetron can be decreased when combined with Fluorouracil.Approved, Withdrawn
AlprazolamThe metabolism of Alprazolam can be decreased when combined with Fluorouracil.Approved, Illicit, Investigational
ALT-110The risk or severity of adverse effects can be increased when Fluorouracil is combined with ALT-110.Investigational
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Fluorouracil.Approved, Withdrawn
AmiodaroneThe metabolism of Amiodarone can be decreased when combined with Fluorouracil.Approved, Investigational
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Fluorouracil.Approved
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Fluorouracil.Approved
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Fluorouracil.Approved
AnvirzelAnvirzel may decrease the cardiotoxic activities of Fluorouracil.Investigational
ApixabanThe metabolism of Apixaban can be decreased when combined with Fluorouracil.Approved
Arachidonic AcidThe metabolism of Arachidonic Acid can be decreased when combined with Fluorouracil.Experimental
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Fluorouracil.Approved, Investigational
ArtemetherThe metabolism of Artemether can be decreased when combined with Fluorouracil.Approved
AtazanavirThe metabolism of Atazanavir can be decreased when combined with Fluorouracil.Approved, Investigational
AzelastineThe metabolism of Azelastine can be decreased when combined with Fluorouracil.Approved
AzithromycinThe metabolism of Fluorouracil can be decreased when combined with Azithromycin.Approved
BCGThe therapeutic efficacy of Bcg can be decreased when used in combination with Fluorouracil.Investigational
BevacizumabBevacizumab may increase the cardiotoxic activities of Fluorouracil.Approved, Investigational
BexaroteneThe metabolism of Bexarotene can be decreased when combined with Fluorouracil.Approved, Investigational
BortezomibThe metabolism of Bortezomib can be decreased when combined with Fluorouracil.Approved, Investigational
BosentanThe serum concentration of Bosentan can be increased when it is combined with Fluorouracil.Approved, Investigational
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Fluorouracil.Approved
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Fluorouracil.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Bupropion can be decreased when combined with Fluorouracil.Approved
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Fluorouracil.Approved
CabozantinibThe metabolism of Cabozantinib can be decreased when combined with Fluorouracil.Approved
CaffeineThe metabolism of Caffeine can be decreased when combined with Fluorouracil.Approved
CandesartanThe metabolism of Candesartan can be decreased when combined with Fluorouracil.Approved
CarbamazepineThe metabolism of Fluorouracil can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Fluorouracil.Approved
CarvedilolThe serum concentration of Carvedilol can be increased when it is combined with Fluorouracil.Approved, Investigational
CDX-110The risk or severity of adverse effects can be increased when Fluorouracil is combined with CDX-110.Investigational
CelecoxibThe metabolism of Celecoxib can be decreased when combined with Fluorouracil.Approved, Investigational
ChlorpropamideThe metabolism of Chlorpropamide can be decreased when combined with Fluorouracil.Approved
CimetidineThe serum concentration of Fluorouracil can be increased when it is combined with Cimetidine.Approved
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Fluorouracil.Approved
CisaprideThe metabolism of Cisapride can be decreased when combined with Fluorouracil.Approved, Investigational, Withdrawn
CitalopramThe metabolism of Fluorouracil can be decreased when combined with Citalopram.Approved
ClopidogrelThe metabolism of Clopidogrel can be decreased when combined with Fluorouracil.Approved, Nutraceutical
ClotrimazoleThe metabolism of Fluorouracil can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Fluorouracil is combined with Clozapine.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Fluorouracil.Approved, Investigational
Cyproterone acetateThe serum concentration of Fluorouracil can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
DabrafenibThe serum concentration of Fluorouracil can be decreased when it is combined with Dabrafenib.Approved
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Fluorouracil.Approved
DapsoneThe metabolism of Dapsone can be decreased when combined with Fluorouracil.Approved, Investigational
DeferasiroxThe serum concentration of Fluorouracil can be increased when it is combined with Deferasirox.Approved, Investigational
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Fluorouracil.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Fluorouracil.Approved
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Fluorouracil.Approved
DiazepamThe metabolism of Diazepam can be decreased when combined with Fluorouracil.Approved, Illicit, Vet Approved
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Fluorouracil.Approved, Vet Approved
DiclofenacThe serum concentration of Diclofenac can be increased when it is combined with Fluorouracil.Approved, Vet Approved
DicoumarolThe serum concentration of Dicoumarol can be increased when it is combined with Fluorouracil.Approved
DicoumarolThe metabolism of Dicoumarol can be decreased when combined with Fluorouracil.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Fluorouracil.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Fluorouracil.Approved
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Fluorouracil.Approved
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Fluorouracil.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Fluorouracil.Approved, Investigational
DolasetronThe metabolism of Dolasetron can be decreased when combined with Fluorouracil.Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Fluorouracil.Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Fluorouracil.Approved
DorzolamideThe metabolism of Dorzolamide can be decreased when combined with Fluorouracil.Approved
DoxepinThe metabolism of Doxepin can be decreased when combined with Fluorouracil.Approved
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Fluorouracil.Approved, Illicit
EfavirenzThe metabolism of Fluorouracil can be decreased when combined with Efavirenz.Approved, Investigational
EletriptanThe metabolism of Eletriptan can be decreased when combined with Fluorouracil.Approved, Investigational
EltrombopagThe serum concentration of Fluorouracil can be increased when it is combined with Eltrombopag.Approved
EpoprostenolThe metabolism of Epoprostenol can be decreased when combined with Fluorouracil.Approved
EstradiolThe metabolism of Estradiol can be decreased when combined with Fluorouracil.Approved, Investigational, Vet Approved
EstroneThe metabolism of Estrone can be decreased when combined with Fluorouracil.Approved
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Fluorouracil.Approved
Ethyl biscoumacetateThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Fluorouracil.Withdrawn
EtodolacThe metabolism of Etodolac can be decreased when combined with Fluorouracil.Approved, Investigational, Vet Approved
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Fluorouracil.Approved, Investigational
EtravirineThe metabolism of Etravirine can be decreased when combined with Fluorouracil.Approved
FelodipineThe metabolism of Fluorouracil can be decreased when combined with Felodipine.Approved, Investigational
FingolimodFluorouracil may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FluindioneThe serum concentration of Fluindione can be increased when it is combined with Fluorouracil.Investigational
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Fluorouracil.Approved
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Fluorouracil.Approved, Illicit
FluoxetineThe metabolism of Fluoxetine can be decreased when combined with Fluorouracil.Approved, Vet Approved
FlurbiprofenThe metabolism of Flurbiprofen can be decreased when combined with Fluorouracil.Approved, Investigational
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Fluorouracil.Approved
FluvoxamineThe metabolism of Fluorouracil can be decreased when combined with Fluvoxamine.Approved, Investigational
FormoterolThe metabolism of Formoterol can be decreased when combined with Fluorouracil.Approved, Investigational
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Fluorouracil.Approved
FosphenytoinThe metabolism of Fosphenytoin can be decreased when combined with Fluorouracil.Approved
G17DTThe risk or severity of adverse effects can be increased when Fluorouracil is combined with G17DT.Investigational
GavestinelThe metabolism of Gavestinel can be decreased when combined with Fluorouracil.Investigational
GemcitabineThe serum concentration of Fluorouracil can be increased when it is combined with Gemcitabine.Approved
GemfibrozilThe metabolism of Fluorouracil can be decreased when combined with Gemfibrozil.Approved
GI-5005The risk or severity of adverse effects can be increased when Fluorouracil is combined with GI-5005.Investigational
GimeracilThe serum concentration of Fluorouracil can be increased when it is combined with Gimeracil.Approved
GliclazideThe metabolism of Gliclazide can be decreased when combined with Fluorouracil.Approved
GlimepirideThe metabolism of Glimepiride can be decreased when combined with Fluorouracil.Approved
GlipizideThe metabolism of Glipizide can be decreased when combined with Fluorouracil.Approved
GlyburideThe metabolism of Glyburide can be decreased when combined with Fluorouracil.Approved
GuanfacineThe metabolism of Guanfacine can be decreased when combined with Fluorouracil.Approved, Investigational
HaloperidolThe metabolism of Haloperidol can be decreased when combined with Fluorouracil.Approved
HalothaneThe metabolism of Halothane can be decreased when combined with Fluorouracil.Approved, Vet Approved
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Fluorouracil.Approved
Histamine PhosphateThe metabolism of Histamine Phosphate can be decreased when combined with Fluorouracil.Approved
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Fluorouracil.Approved, Illicit
IbuprofenThe metabolism of Ibuprofen can be decreased when combined with Fluorouracil.Approved
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Fluorouracil.Approved
IfosfamideThe metabolism of Ifosfamide can be decreased when combined with Fluorouracil.Approved
ImatinibThe metabolism of Imatinib can be decreased when combined with Fluorouracil.Approved
indisulamThe metabolism of indisulam can be decreased when combined with Fluorouracil.Investigational
IndomethacinThe metabolism of Indomethacin can be decreased when combined with Fluorouracil.Approved, Investigational
INGN 201The risk or severity of adverse effects can be increased when Fluorouracil is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Fluorouracil is combined with INGN 225.Investigational
IrbesartanThe metabolism of Irbesartan can be decreased when combined with Fluorouracil.Approved, Investigational
IxazomibThe metabolism of Ixazomib can be decreased when combined with Fluorouracil.Approved
KetamineThe metabolism of Ketamine can be decreased when combined with Fluorouracil.Approved, Vet Approved
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Fluorouracil.Approved
KetoprofenThe metabolism of Ketoprofen can be decreased when combined with Fluorouracil.Approved, Vet Approved
LacosamideThe serum concentration of Lacosamide can be increased when it is combined with Fluorouracil.Approved
LansoprazoleThe metabolism of Lansoprazole can be decreased when combined with Fluorouracil.Approved, Investigational
LapatinibThe metabolism of Fluorouracil can be decreased when combined with Lapatinib.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Fluorouracil is combined with Leflunomide.Approved, Investigational
LesinuradThe metabolism of Lesinurad can be decreased when combined with Fluorouracil.Approved
LeucovorinThe risk or severity of adverse effects can be increased when Leucovorin is combined with Fluorouracil.Approved
LevoleucovorinThe risk or severity of adverse effects can be increased when Levoleucovorin is combined with Fluorouracil.Approved
LicofeloneThe metabolism of Licofelone can be decreased when combined with Fluorouracil.Investigational
LidocaineThe metabolism of Lidocaine can be decreased when combined with Fluorouracil.Approved, Vet Approved
LopinavirThe metabolism of Fluorouracil can be decreased when combined with Lopinavir.Approved
LoratadineThe metabolism of Loratadine can be decreased when combined with Fluorouracil.Approved
LornoxicamThe metabolism of Lornoxicam can be decreased when combined with Fluorouracil.Approved
LosartanThe metabolism of Losartan can be decreased when combined with Fluorouracil.Approved
LumacaftorThe serum concentration of Fluorouracil can be increased when it is combined with Lumacaftor.Approved
LumiracoxibThe metabolism of Lumiracoxib can be decreased when combined with Fluorouracil.Approved, Investigational
Mefenamic acidThe metabolism of Mefenamic acid can be decreased when combined with Fluorouracil.Approved
MelatoninThe metabolism of Melatonin can be decreased when combined with Fluorouracil.Approved, Nutraceutical, Vet Approved
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Fluorouracil.Approved, Vet Approved
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Fluorouracil.Investigational, Withdrawn
MestranolThe metabolism of Mestranol can be decreased when combined with Fluorouracil.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Fluorouracil.Withdrawn
MethadoneThe metabolism of Methadone can be decreased when combined with Fluorouracil.Approved
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Fluorouracil.Approved, Vet Approved
MetronidazoleThe metabolism of Metronidazole can be decreased when combined with Fluorouracil.Approved
MetronidazoleThe serum concentration of Fluorouracil can be increased when it is combined with Metronidazole.Approved
MexiletineThe metabolism of Fluorouracil can be decreased when combined with Mexiletine.Approved
MifepristoneThe serum concentration of Fluorouracil can be increased when it is combined with Mifepristone.Approved, Investigational
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Fluorouracil.Approved
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Fluorouracil.Approved
MontelukastThe metabolism of Montelukast can be decreased when combined with Fluorouracil.Approved
NaproxenThe metabolism of Naproxen can be decreased when combined with Fluorouracil.Approved, Vet Approved
NatalizumabThe risk or severity of adverse effects can be increased when Fluorouracil is combined with Natalizumab.Approved, Investigational
NateglinideThe metabolism of Nateglinide can be decreased when combined with Fluorouracil.Approved, Investigational
NetupitantThe metabolism of Netupitant can be decreased when combined with Fluorouracil.Approved
NevirapineThe metabolism of Nevirapine can be decreased when combined with Fluorouracil.Approved
NiclosamideThe metabolism of Niclosamide can be decreased when combined with Fluorouracil.Approved, Vet Approved
NicotineThe metabolism of Nicotine can be decreased when combined with Fluorouracil.Approved
NilotinibThe metabolism of Fluorouracil can be decreased when combined with Nilotinib.Approved, Investigational
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Fluorouracil.Approved
OlodaterolThe metabolism of Olodaterol can be decreased when combined with Fluorouracil.Approved
OmeprazoleThe metabolism of Omeprazole can be decreased when combined with Fluorouracil.Approved, Investigational, Vet Approved
OndansetronThe metabolism of Ondansetron can be decreased when combined with Fluorouracil.Approved
OsimertinibThe serum concentration of Fluorouracil can be decreased when it is combined with Osimertinib.Approved
OspemifeneThe serum concentration of Ospemifene can be increased when it is combined with Fluorouracil.Approved
OuabainOuabain may decrease the cardiotoxic activities of Fluorouracil.Approved
OxaprozinThe metabolism of Oxaprozin can be decreased when combined with Fluorouracil.Approved
PaclitaxelThe metabolism of Paclitaxel can be decreased when combined with Fluorouracil.Approved, Vet Approved
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Fluorouracil.Approved
ParecoxibThe serum concentration of Parecoxib can be increased when it is combined with Fluorouracil.Approved
Peginterferon alfa-2bThe serum concentration of Fluorouracil can be increased when it is combined with Peginterferon alfa-2b.Approved
PentobarbitalThe metabolism of Fluorouracil can be increased when combined with Pentobarbital.Approved, Vet Approved
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Fluorouracil.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Fluorouracil.Withdrawn
PhenindioneThe serum concentration of Phenindione can be increased when it is combined with Fluorouracil.Approved
PhenobarbitalThe metabolism of Fluorouracil can be increased when combined with Phenobarbital.Approved
PhenprocoumonThe serum concentration of Phenprocoumon can be increased when it is combined with Fluorouracil.Approved
PhenprocoumonThe metabolism of Phenprocoumon can be decreased when combined with Fluorouracil.Approved
PhenylbutazoneThe metabolism of Phenylbutazone can be decreased when combined with Fluorouracil.Approved, Vet Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Fluorouracil.Approved, Vet Approved
PhenytoinThe metabolism of Phenytoin can be decreased when combined with Fluorouracil.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Fluorouracil.Approved, Investigational
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Fluorouracil.Approved, Investigational
PiroxicamThe metabolism of Piroxicam can be decreased when combined with Fluorouracil.Approved, Investigational
PitavastatinThe metabolism of Pitavastatin can be decreased when combined with Fluorouracil.Approved
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Fluorouracil.Approved
PravastatinThe metabolism of Pravastatin can be decreased when combined with Fluorouracil.Approved
PrimidoneThe metabolism of Fluorouracil can be increased when combined with Primidone.Approved, Vet Approved
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Fluorouracil.Approved, Vet Approved
ProguanilThe metabolism of Proguanil can be decreased when combined with Fluorouracil.Approved
PromazineThe metabolism of Promazine can be decreased when combined with Fluorouracil.Approved, Vet Approved
PropofolThe metabolism of Propofol can be decreased when combined with Fluorouracil.Approved, Investigational, Vet Approved
QuazepamThe metabolism of Quazepam can be decreased when combined with Fluorouracil.Approved, Illicit
QuinidineThe metabolism of Quinidine can be decreased when combined with Fluorouracil.Approved
QuinineThe metabolism of Quinine can be decreased when combined with Fluorouracil.Approved
RabeprazoleThe metabolism of Fluorouracil can be decreased when combined with Rabeprazole.Approved, Investigational
Rabies vaccineThe risk or severity of adverse effects can be increased when Fluorouracil is combined with Rabies vaccine.Approved
Rabies vaccineThe therapeutic efficacy of Rabies vaccine can be decreased when used in combination with Fluorouracil.Approved
RamelteonThe serum concentration of Ramelteon can be increased when it is combined with Fluorouracil.Approved, Investigational
RifampicinThe metabolism of Fluorouracil can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Fluorouracil can be increased when combined with Rifapentine.Approved
RitonavirThe metabolism of Fluorouracil can be decreased when combined with Ritonavir.Approved, Investigational
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Fluorouracil.Investigational, Withdrawn
RoflumilastRoflumilast may increase the immunosuppressive activities of Fluorouracil.Approved
RolapitantThe serum concentration of Fluorouracil can be increased when it is combined with Rolapitant.Approved
RopiniroleThe metabolism of Fluorouracil can be decreased when combined with Ropinirole.Approved, Investigational
RosiglitazoneThe metabolism of Rosiglitazone can be decreased when combined with Fluorouracil.Approved, Investigational
RosuvastatinThe metabolism of Rosuvastatin can be decreased when combined with Fluorouracil.Approved
Salicylic acidThe metabolism of Salicylic acid can be decreased when combined with Fluorouracil.Approved, Vet Approved
SecobarbitalThe metabolism of Fluorouracil can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineThe metabolism of Selegiline can be decreased when combined with Fluorouracil.Approved, Investigational, Vet Approved
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Fluorouracil.Approved, Investigational
SertralineThe metabolism of Sertraline can be decreased when combined with Fluorouracil.Approved
SildenafilThe metabolism of Sildenafil can be decreased when combined with Fluorouracil.Approved, Investigational
SimeprevirThe metabolism of Fluorouracil can be decreased when combined with Simeprevir.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Fluorouracil.Approved
SitaxentanThe metabolism of Sitaxentan can be decreased when combined with Fluorouracil.Approved, Investigational, Withdrawn
SorafenibThe serum concentration of Fluorouracil can be decreased when it is combined with Sorafenib.Approved, Investigational
SRP 299The risk or severity of adverse effects can be increased when Fluorouracil is combined with SRP 299.Investigational
StiripentolThe metabolism of Fluorouracil can be decreased when combined with Stiripentol.Approved
SulfadiazineThe metabolism of Sulfadiazine can be decreased when combined with Fluorouracil.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Sulfamethoxazole can be decreased when combined with Fluorouracil.Approved
SulfamoxoleThe metabolism of Sulfamoxole can be decreased when combined with Fluorouracil.Approved
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Fluorouracil.Approved
SulfisoxazoleThe metabolism of Sulfisoxazole can be decreased when combined with Fluorouracil.Approved, Vet Approved
SuprofenThe metabolism of Suprofen can be decreased when combined with Fluorouracil.Approved, Withdrawn
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Fluorouracil.Approved, Investigational
TamoxifenThe metabolism of Tamoxifen can be decreased when combined with Fluorouracil.Approved
TapentadolThe metabolism of Tapentadol can be decreased when combined with Fluorouracil.Approved
TemazepamThe metabolism of Temazepam can be decreased when combined with Fluorouracil.Approved
TenofovirThe metabolism of Fluorouracil can be decreased when combined with Tenofovir.Approved, Investigational
TenoxicamThe metabolism of Tenoxicam can be decreased when combined with Fluorouracil.Approved
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Fluorouracil.Approved, Investigational, Vet Approved
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Fluorouracil.Withdrawn
TeriflunomideThe serum concentration of Fluorouracil can be decreased when it is combined with Teriflunomide.Approved
TestosteroneThe metabolism of Testosterone can be decreased when combined with Fluorouracil.Approved, Investigational
TG4010The risk or severity of adverse effects can be increased when Fluorouracil is combined with TG4010.Investigational
ThalidomideThe metabolism of Thalidomide can be decreased when combined with Fluorouracil.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Theophylline can be decreased when combined with Fluorouracil.Approved
ThiamylalThe metabolism of Thiamylal can be decreased when combined with Fluorouracil.Approved, Vet Approved
TiclopidineThe metabolism of Fluorouracil can be decreased when combined with Ticlopidine.Approved
TofacitinibFluorouracil may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TolbutamideThe metabolism of Tolbutamide can be decreased when combined with Fluorouracil.Approved
TolterodineThe metabolism of Tolterodine can be decreased when combined with Fluorouracil.Approved, Investigational
TorasemideThe metabolism of Torasemide can be decreased when combined with Fluorouracil.Approved
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Fluorouracil.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Fluorouracil.Approved, Investigational
TreprostinilThe metabolism of Treprostinil can be decreased when combined with Fluorouracil.Approved, Investigational
TretinoinThe metabolism of Tretinoin can be decreased when combined with Fluorouracil.Approved, Investigational, Nutraceutical
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Fluorouracil.Approved
TrimethoprimThe metabolism of Trimethoprim can be decreased when combined with Fluorouracil.Approved, Vet Approved
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Fluorouracil.Approved
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Fluorouracil.Withdrawn
ValdecoxibThe metabolism of Valdecoxib can be decreased when combined with Fluorouracil.Investigational, Withdrawn
Valproic AcidThe metabolism of Valproic Acid can be decreased when combined with Fluorouracil.Approved, Investigational
ValsartanThe metabolism of Valsartan can be decreased when combined with Fluorouracil.Approved, Investigational
VemurafenibThe serum concentration of Fluorouracil can be increased when it is combined with Vemurafenib.Approved
VenlafaxineThe metabolism of Venlafaxine can be decreased when combined with Fluorouracil.Approved
VerapamilThe metabolism of Verapamil can be decreased when combined with Fluorouracil.Approved
VicrivirocThe metabolism of Vicriviroc can be decreased when combined with Fluorouracil.Investigational
VismodegibThe metabolism of Vismodegib can be decreased when combined with Fluorouracil.Approved
VoriconazoleThe metabolism of Voriconazole can be decreased when combined with Fluorouracil.Approved, Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Fluorouracil.Approved
WarfarinThe serum concentration of Warfarin can be increased when it is combined with Fluorouracil.Approved
WarfarinThe metabolism of Warfarin can be decreased when combined with Fluorouracil.Approved
XimelagatranThe metabolism of Ximelagatran can be decreased when combined with Fluorouracil.Approved, Investigational, Withdrawn
ZafirlukastThe metabolism of Zafirlukast can be decreased when combined with Fluorouracil.Approved, Investigational
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Fluorouracil.Approved
ZaltoprofenThe metabolism of Zaltoprofen can be decreased when combined with Fluorouracil.Approved
ZidovudineThe metabolism of Zidovudine can be decreased when combined with Fluorouracil.Approved
ZileutonThe metabolism of Zileuton can be decreased when combined with Fluorouracil.Approved, Investigational, Withdrawn
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Fluorouracil.Approved
ZopicloneThe metabolism of Zopiclone can be decreased when combined with Fluorouracil.Approved
Food Interactions
  • Vitamin B1 needs increased with long term use.
References
Synthesis Reference

Leroy B. Townsend, Robert A. Earl, Steven J. Manning, “Method of synthesizing 1-(tetrahydro-2-furanyl)-5-fluorouracil.” U.S. Patent US3960864, issued October, 1969.

US3960864
General References
  1. Longley DB, Harkin DP, Johnston PG: 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003 May;3(5):330-8. [PubMed:12724731 ]
  2. Petty RD, Cassidy J: Novel fluoropyrimidines: improving the efficacy and tolerability of cytotoxic therapy. Curr Cancer Drug Targets. 2004 Mar;4(2):191-204. [PubMed:15032669 ]
External Links
ATC CodesL01BC02L01BC52
AHFS Codes
  • 10:00.00
  • 84:92.00
PDB Entries
FDA labelDownload (378 KB)
MSDSDownload (74 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9605
Blood Brain Barrier+0.9791
Caco-2 permeable-0.7583
P-glycoprotein substrateNon-substrate0.7752
P-glycoprotein inhibitor INon-inhibitor0.8991
P-glycoprotein inhibitor IINon-inhibitor1.0
Renal organic cation transporterNon-inhibitor0.9053
CYP450 2C9 substrateNon-substrate0.7898
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.7558
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9658
CYP450 2D6 inhibitorNon-inhibitor0.9361
CYP450 2C19 inhibitorNon-inhibitor0.9688
CYP450 3A4 inhibitorNon-inhibitor0.9661
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9839
Ames testNon AMES toxic0.8941
CarcinogenicityNon-carcinogens0.9288
BiodegradationNot ready biodegradable0.922
Rat acute toxicity2.2529 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9685
hERG inhibition (predictor II)Non-inhibitor0.9325
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Sanofi aventis us llc
  • Valeant pharmaceuticals international
  • Allergan herbert skin care div allergan inc
  • Spear pharmaceuticals inc
  • Taro pharmaceutical industries ltd
  • Pharmacia and upjohn co
  • Teva parenteral medicines inc
  • Abic ltd
  • Abraxis pharmaceutical products
  • App pharmaceuticals llc
  • Bedford laboratories div ben venue laboratories inc
  • Bioniche pharma usa llc
  • Ebewe pharma ges mbh nfg kg
  • Marchar laboratories inc ltd
  • Smith and nephew solopak div smith and nephew
  • Watson laboratories inc
  • Elorac inc
  • Taro pharmaceuticals usa inc
Packagers
Dosage forms
FormRouteStrength
SolutionTopical
Injection, solutionIntravenous2.5 g/50mL
Injection, solutionIntravenous5 g/100mL
LiquidIntravenous500 mg
CreamTopical5 mg/g
CreamTopical2 g/40g
CreamTopical5 %
CreamTopical10 mg/g
CreamTopical1 %
CreamTopical50 mg/g
Injection, solutionIntravenous50 mg/mL
SolutionTopical20 mg/mL
SolutionTopical50 mg/mL
LiquidIntravenous50 mg
SolutionIntravenous5 g
SolutionIntravenous50 mg
CreamTopical.04 g/g
Prices
Unit descriptionCostUnit
Efudex 5% Cream 40 gm Tube478.39USD tube
Fluoroplex 1% Cream 30 gm Tube268.61USD tube
Fluorouracil 5% Cream 40 gm Tube249.98USD tube
Carac 0.5% Cream 30 gm Tube209.77USD tube
Efudex 5% Solution 10ml Bottle136.51USD bottle
Fluorouracil 5% Solution 10ml Bottle115.78USD bottle
Fluorouracil 2% Solution 10ml Bottle78.63USD bottle
Efudex 5% cream10.28USD g
Fluorouracil 5% cream9.62USD g
Fluorouracil powder8.45USD g
Fluoroplex 1% cream7.85USD g
Carac cream6.43USD g
Efudex 50 mg/g Cream0.9USD g
Fluorouracil 50 mg/ml Solution0.52USD ml
Adrucil 50 mg/ml vial0.4USD ml
Fluorouracil 5000 mg/100 ml0.28USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6670335 No2001-06-022021-06-02Us
US7169401 No2003-07-182023-07-18Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point282-283Heidelberger, C. and Duschinsky, R.; US. Patent 2,802,005; August 6, 1957. Heidelberger, C. and Duschinsky, R.; U.S.Patent 2,885,396; May 5, 1959.
water solubility1.11E+004 mg/L (at 22 °C)BURR,A & BUNDGAARD,H (1985)
logP-0.89HANSCH,C ET AL. (1995)
logS-1.07ADME Research, USCD
pKa8.02SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility5.86 mg/mLALOGPS
logP-0.58ALOGPS
logP-0.66ChemAxon
logS-1.4ALOGPS
pKa (Strongest Acidic)7.76ChemAxon
pKa (Strongest Basic)-8ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area58.2 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity26.17 m3·mol-1ChemAxon
Polarizability9.46 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (7.93 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, Positivesplash10-001i-1900000000-3fa9b91447db7dc7ba77View in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, Positivesplash10-01q9-9800000000-32bf878787078ce9d817View in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, Positivesplash10-03di-9000000000-3ef559051a5b99c94b29View in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, Negativesplash10-004i-4900000000-82764fbca3290816328dView in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, Negativesplash10-000f-9100000000-2da5eb3c925c027b5022View in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, Negativesplash10-0006-9000000000-1cf432837297c55833a5View in MoNA
MSMass Spectrum (Electron Ionization)splash10-001i-9400000000-b8247c8f5c45b12efaa6View in MoNA
1D NMR1H NMR SpectrumNot Available
Taxonomy
DescriptionThis compound belongs to the class of chemical entities known as halopyrimidines. These are aromatic compounds containing a halogen atom linked to a pyrimidine ring. Pyrimidine is a 6-membered ring consisting of four carbon atoms and two nitrogen centers at the 1- and 3- ring positions.
KingdomChemical entities
Super ClassOrganic compounds
ClassOrganoheterocyclic compounds
Sub ClassDiazines
Direct ParentHalopyrimidines
Alternative Parents
Substituents
  • Hydroxypyrimidine
  • Halopyrimidine
  • Aryl halide
  • Aryl fluoride
  • Heteroaromatic compound
  • Azacycle
  • Organic nitrogen compound
  • Organic oxygen compound
  • Organopnictogen compound
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organofluoride
  • Organohalogen compound
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
other/unknown
General Function:
Thymidylate synthase activity
Specific Function:
Contributes to the de novo mitochondrial thymidylate biosynthesis pathway.
Gene Name:
TYMS
Uniprot ID:
P04818
Molecular Weight:
35715.65 Da
References
  1. Formentini A, Sander S, Denzer S, Straeter J, Henne-Bruns D, Kornmann M: Thymidylate synthase expression in resectable and unresectable pancreatic cancer: role as predictive or prognostic marker? Int J Colorectal Dis. 2007 Jan;22(1):49-55. Epub 2006 Mar 15. [PubMed:16538493 ]
  2. Huang CL, Yokomise H, Fukushima M, Kinoshita M: Tailor-made chemotherapy for non-small cell lung cancer patients. Future Oncol. 2006 Apr;2(2):289-99. [PubMed:16563096 ]
  3. Fernandez-Contreras ME, Sanchez-Prudencio S, Sanchez-Hernandez JJ, Garcia de Paredes ML, Gisbert JP, Roda-Navarro P, Gamallo C: Thymidylate synthase expression pattern, expression level and single nucleotide polymorphism are predictors for disease-free survival in patients of colorectal cancer treated with 5-fluorouracil. Int J Oncol. 2006 May;28(5):1303-10. [PubMed:16596248 ]
  4. Garcia V, Garcia JM, Pena C, Silva J, Dominguez G, Hurtado A, Alonso I, Rodriguez R, Provencio M, Bonilla F: Thymidylate synthase messenger RNA expression in plasma from patients with colon cancer: prognostic potential. Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2095-100. [PubMed:16609021 ]
  5. Ploylearmsaeng SA, Fuhr U, Jetter A: How may anticancer chemotherapy with fluorouracil be individualised? Clin Pharmacokinet. 2006;45(6):567-92. [PubMed:16719540 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  7. Rustum YM: Thymidylate synthase: a critical target in cancer therapy? Front Biosci. 2004 Sep 1;9:2467-73. [PubMed:15353299 ]
2. DNA
Kind
Nucleotide
Organism
Human
Pharmacological action
yes
Actions
incorporation into and destabilization
General Function:
Used for biological information storage.
Specific Function:
DNA contains the instructions needed for an organism to develop, survive and reproduce.
Molecular Weight:
2.15 x 1012 Da
References
  1. Wyatt MD, Wilson DM 3rd: Participation of DNA repair in the response to 5-fluorouracil. Cell Mol Life Sci. 2009 Mar;66(5):788-99. doi: 10.1007/s00018-008-8557-5. [PubMed:18979208 ]
  2. Ghoshal K, Jacob ST: An alternative molecular mechanism of action of 5-fluorouracil, a potent anticancer drug. Biochem Pharmacol. 1997 Jun 1;53(11):1569-75. [PubMed:9264308 ]
  3. Longley DB, Harkin DP, Johnston PG: 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003 May;3(5):330-8. [PubMed:12724731 ]
  4. Petty RD, Cassidy J: Novel fluoropyrimidines: improving the efficacy and tolerability of cytotoxic therapy. Curr Cancer Drug Targets. 2004 Mar;4(2):191-204. [PubMed:15032669 ]
3. RNA
Kind
Nucleotide
Organism
Human
Pharmacological action
yes
Actions
incorporation into and destabilization
References
  1. Wyatt MD, Wilson DM 3rd: Participation of DNA repair in the response to 5-fluorouracil. Cell Mol Life Sci. 2009 Mar;66(5):788-99. doi: 10.1007/s00018-008-8557-5. [PubMed:18979208 ]
  2. Ghoshal K, Jacob ST: An alternative molecular mechanism of action of 5-fluorouracil, a potent anticancer drug. Biochem Pharmacol. 1997 Jun 1;53(11):1569-75. [PubMed:9264308 ]
  3. Longley DB, Harkin DP, Johnston PG: 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003 May;3(5):330-8. [PubMed:12724731 ]
  4. Petty RD, Cassidy J: Novel fluoropyrimidines: improving the efficacy and tolerability of cytotoxic therapy. Curr Cancer Drug Targets. 2004 Mar;4(2):191-204. [PubMed:15032669 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Transferase activity, transferring pentosyl groups
Specific Function:
May have a role in maintaining the integrity of the blood vessels. Has growth promoting activity on endothelial cells, angiogenic activity in vivo and chemotactic activity on endothelial cells in vitro.Catalyzes the reversible phosphorolysis of thymidine. The produced molecules are then utilized as carbon and energy sources or in the rescue of pyrimidine bases for nucleotide synthesis.
Gene Name:
TYMP
Uniprot ID:
P19971
Molecular Weight:
49954.965 Da
References
  1. Scartozzi M, Maccaroni E, Giampieri R, Pistelli M, Bittoni A, Del Prete M, Berardi R, Cascinu S: 5-Fluorouracil pharmacogenomics: still rocking after all these years? Pharmacogenomics. 2011 Feb;12(2):251-65. doi: 10.2217/pgs.10.167. [PubMed:21332317 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Protein homodimerization activity
Specific Function:
Involved in pyrimidine base degradation. Catalyzes the reduction of uracil and thymine. Also involved the degradation of the chemotherapeutic drug 5-fluorouracil.
Gene Name:
DPYD
Uniprot ID:
Q12882
Molecular Weight:
111400.32 Da
References
  1. Ho DH, Townsend L, Luna MA, Bodey GP: Distribution and inhibition of dihydrouracil dehydrogenase activities in human tissues using 5-fluorouracil as a substrate. Anticancer Res. 1986 Jul-Aug;6(4):781-4. [PubMed:3752956 ]
  2. Keizer HJ, De Bruijn EA, Tjaden UR, De Clercq E: Inhibition of fluorouracil catabolism in cancer patients by the antiviral agent (E)-5-(2-bromovinyl)-2'-deoxyuridine. J Cancer Res Clin Oncol. 1994;120(9):545-9. [PubMed:8045919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Uridine phosphorylase activity
Specific Function:
Catalyzes the reversible phosphorylytic cleavage of uridine and deoxyuridine to uracil and ribose- or deoxyribose-1-phosphate (PubMed:7488099). The produced molecules are then utilized as carbon and energy sources or in the rescue of pyrimidine bases for nucleotide synthesis.
Gene Name:
UPP1
Uniprot ID:
Q16831
Molecular Weight:
33934.005 Da
References
  1. Yan R, Wan L, Pizzorno G, Cao D: Uridine phosphorylase in breast cancer: a new prognostic factor? Front Biosci. 2006 Sep 1;11:2759-66. [PubMed:16720348 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Uridine phosphorylase activity
Specific Function:
Catalyzes the reversible phosphorylytic cleavage of uridine and deoxyuridine to uracil and ribose- or deoxyribose-1-phosphate. The produced molecules are then utilized as carbon and energy sources or in the rescue of pyrimidine bases for nucleotide synthesis. Shows substrate specificity and accept uridine, deoxyuridine, and thymidine as well as the two pyrimidine nucleoside analogs 5-fluorourid...
Gene Name:
UPP2
Uniprot ID:
O95045
Molecular Weight:
35526.93 Da
References
  1. Yan R, Wan L, Pizzorno G, Cao D: Uridine phosphorylase in breast cancer: a new prognostic factor? Front Biosci. 2006 Sep 1;11:2759-66. [PubMed:16720348 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Constitutes the major nicotine C-oxidase. Acts as a 1,4-cineole 2-exo-monooxygenase. Possesses low phenacetin O-deethylation activity.
Gene Name:
CYP2A6
Uniprot ID:
P11509
Molecular Weight:
56501.005 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Protein complex binding
Specific Function:
Catalyzes the conversion of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, a co-substrate for homocysteine remethylation to methionine.
Gene Name:
MTHFR
Uniprot ID:
P42898
Molecular Weight:
74595.895 Da
References
  1. Scartozzi M, Maccaroni E, Giampieri R, Pistelli M, Bittoni A, Del Prete M, Berardi R, Cascinu S: 5-Fluorouracil pharmacogenomics: still rocking after all these years? Pharmacogenomics. 2011 Feb;12(2):251-65. doi: 10.2217/pgs.10.167. [PubMed:21332317 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Thymidylate synthase activity
Specific Function:
Contributes to the de novo mitochondrial thymidylate biosynthesis pathway.
Gene Name:
TYMS
Uniprot ID:
P04818
Molecular Weight:
35715.65 Da
References
  1. Scartozzi M, Maccaroni E, Giampieri R, Pistelli M, Bittoni A, Del Prete M, Berardi R, Cascinu S: 5-Fluorouracil pharmacogenomics: still rocking after all these years? Pharmacogenomics. 2011 Feb;12(2):251-65. doi: 10.2217/pgs.10.167. [PubMed:21332317 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Orotidine-5'-phosphate decarboxylase activity
Specific Function:
Not Available
Gene Name:
UMPS
Uniprot ID:
P11172
Molecular Weight:
52221.075 Da
References
  1. Link [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Metal ion binding
Specific Function:
Not Available
Gene Name:
PPAT
Uniprot ID:
Q06203
Molecular Weight:
57398.52 Da
References
  1. Link [Link]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
no
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Molecular Weight:
69365.94 Da
References
  1. Sulkowska A, Bojko B, Rownicka J, Sulkowski W: Competition of drugs to serum albumin in combination therapy. Biopolymers. 2004 Jun 15;74(3):256-62. [PubMed:15150801 ]
  2. Bertucci C, Ascoli G, Uccello-Barretta G, Di Bari L, Salvadori P: The binding of 5-fluorouracil to native and modified human serum albumin: UV, CD, and 1H and 19F NMR investigation. J Pharm Biomed Anal. 1995 Aug;13(9):1087-93. [PubMed:8573632 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates sodium-independent multispecific organic anion transport. Transport of prostaglandin E2, prostaglandin F2, tetracycline, bumetanide, estrone sulfate, glutarate, dehydroepiandrosterone sulfate, allopurinol, 5-fluorouracil, paclitaxel, L-ascorbic acid, salicylate, ethotrexate, and alpha-ketoglutarate.
Gene Name:
SLC22A7
Uniprot ID:
Q9Y694
Molecular Weight:
60025.025 Da
References
  1. Kobayashi Y, Ohshiro N, Sakai R, Ohbayashi M, Kohyama N, Yamamoto T: Transport mechanism and substrate specificity of human organic anion transporter 2 (hOat2 [SLC22A7]). J Pharm Pharmacol. 2005 May;57(5):573-8. [PubMed:15901346 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Nucleoside transmembrane transporter activity
Specific Function:
Mediates both influx and efflux of nucleosides across the membrane (equilibrative transporter). It is sensitive (ES) to low concentrations of the inhibitor nitrobenzylmercaptopurine riboside (NBMPR) and is sodium-independent. It has a higher affinity for adenosine. Inhibited by dipyridamole and dilazep (anticancer chemotherapeutics drugs).
Gene Name:
SLC29A1
Uniprot ID:
Q99808
Molecular Weight:
50218.805 Da
References
  1. Tsujie M, Nakamori S, Nakahira S, Takahashi Y, Hayashi N, Okami J, Nagano H, Dono K, Umeshita K, Sakon M, Monden M: Human equilibrative nucleoside transporter 1, as a predictor of 5-fluorouracil resistance in human pancreatic cancer. Anticancer Res. 2007 Jul-Aug;27(4B):2241-9. [PubMed:17695509 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both from mitochondria to cytosol and from cytosol to extracellular space, and cellular export of hemin, and heme. Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from t...
Gene Name:
ABCG2
Uniprot ID:
Q9UNQ0
Molecular Weight:
72313.47 Da
References
  1. Yuan J, Lv H, Peng B, Wang C, Yu Y, He Z: Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer. Cancer Chemother Pharmacol. 2009 May;63(6):1103-10. doi: 10.1007/s00280-008-0838-z. Epub 2008 Sep 27. [PubMed:18820913 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Organic anion transmembrane transporter activity
Specific Function:
May act as an inducible transporter in the biliary and intestinal excretion of organic anions. Acts as an alternative route for the export of bile acids and glucuronides from cholestatic hepatocytes (By similarity).
Gene Name:
ABCC3
Uniprot ID:
O15438
Molecular Weight:
169341.14 Da
References
  1. Hagmann W, Jesnowski R, Faissner R, Guo C, Lohr JM: ATP-binding cassette C transporters in human pancreatic carcinoma cell lines. Upregulation in 5-fluorouracil-resistant cells. Pancreatology. 2009;9(1-2):136-44. doi: 10.1159/000178884. Epub 2008 Dec 13. [PubMed:19077464 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Atpase activity, coupled to transmembrane movement of substances
Specific Function:
May be an organic anion pump relevant to cellular detoxification.
Gene Name:
ABCC4
Uniprot ID:
O15439
Molecular Weight:
149525.33 Da
References
  1. Hagmann W, Jesnowski R, Faissner R, Guo C, Lohr JM: ATP-binding cassette C transporters in human pancreatic carcinoma cell lines. Upregulation in 5-fluorouracil-resistant cells. Pancreatology. 2009;9(1-2):136-44. doi: 10.1159/000178884. Epub 2008 Dec 13. [PubMed:19077464 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Organic anion transmembrane transporter activity
Specific Function:
Acts as a multispecific organic anion pump which can transport nucleotide analogs.
Gene Name:
ABCC5
Uniprot ID:
O15440
Molecular Weight:
160658.8 Da
References
  1. Hagmann W, Jesnowski R, Faissner R, Guo C, Lohr JM: ATP-binding cassette C transporters in human pancreatic carcinoma cell lines. Upregulation in 5-fluorouracil-resistant cells. Pancreatology. 2009;9(1-2):136-44. doi: 10.1159/000178884. Epub 2008 Dec 13. [PubMed:19077464 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on January 22, 2017 02:41